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Date Event Description 
9 January 2017 New citation: conclusions not 
changed 
One new comparison (Two-step approach (50 g oral 
glucose challenge test (OGCT) followed by selective 100 g 
OGTT Carpenter and Coustan criteria) versus one-step 
approach (universal 75 g OGTT ADA criteria)) added in this 
update. Conclusions not changed. 
9 January 2017 Updated Search updated. One trial was included (Turkey 2014 
). One trial is awaiting classification (China 2013). One 
trial was excluded (USA 2015) and a further five trial 
reports were added to a previously excluded trial (Ireland 
2014a). Two trials (four reports) are ongoing (Ireland 2014b; 
USA 2014). 
The following secondary outcomes were added to types of 
outcome measures: Maternal: Perineal trauma, Placental 
abruption, Weight gain during pregnancy, Breastfeeding, 
Neonatal: Apgar Score (less than seven at five minutes), 
Birthweight and Z-score, Ponderal index, Measures of 
adiposity, Shoulder dystocia, Bone fracture, Nerve palsy, 
and Relevant biomarkers (e.g. cord C-peptide, cord insulin). 
History 
Date Event Description 
31 October 2014 New citation: conclusions not 
changed 
Evidence is insufficient to permit assessment of which 
strategy is best for diagnosing GDM. 
31 October 2014 Updated Search updated with 3 new reports identified: 1 trial  
was included (Mexico 2011); 1 was excluded (Ireland 
2014a); and 1 (USA 2013) is ongoing. Methods updated 
and 'Summary of findings' table added. 




Gestational diabetes mellitus (GDM) is carbohydrate intolerance resulting in hyperglycaemia with onset or first recognition 
during pregnancy. If untreated, perinatal morbidity and mortality may be increased. Accurate diagnosis allows appropriate 
treatment. Use of different tests and different criteria will influence which women are diagnosed with GDM. This is an update 
of a review published in 2011 and 2015. 
Objectives 
To evaluate and compare different testing strategies for diagnosis of gestational diabetes mellitus to improve maternal and 
infant health while assessing their impact on healthcare service costs. 
Search methods 
We searched Cochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov, WHO International Clinical 
Trials Registry Platform (ICTRP) (9 January 2017) and reference lists of retrieved studies. 
Selection criteria 
We included randomised trials if they evaluated tests carried out to diagnose GDM. We excluded studies that used a quasi- 
random model, cluster-randomised or cross-over trials. 
Data collection and analysis 
Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for 
accuracy. The quality of the evidence was assessed using the GRADE approach. 
Main results 
We included a total of seven small trials, with 1420 women. One trial including 726 women was identified by this update and 
examined the two step versus one step approach. These trials were assessed as having varying risk of bias, with few 
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outcomes reported. We prespecified six outcomes to be assessed for quality using the GRADE approach for one 
comparison: 75 g oral glucose tolerance test (OGTT) versus 100 g OGTT; data for only one outcome (diagnosis of 
gestational diabetes) were available for assessment. One trial compared three different methods of delivering glucose: a 
candy bar (39 women), a 50 g glucose polymer drink (40 women) and a 50 g glucose monomer drink (43 women). We have 
included the results reported by this trial as separate comparisons. No trial reported on measures of costs of health services. 
We examined six main comparisons. 
75 g OGTT versus 100 g OGTT (1 trial, 248 women): women who received 75 g OGTT had a higher relative risk of being 
diagnosed with GDM (risk ratio (RR) 2.55, 95% confidence interval (CI) 0.96 to 6.75; very-low quality evidence). No data 
were reported for the following additional outcomes prespecified for GRADE assessment: caesarean section, macrosomia > 
4.5 kg or however defined in the trial, long-term type 2 diabetes maternal, long-term type 2 diabetes infant and economic 
costs. 
Candy bar versus 50 g glucose monomer drink (1 trial, 60 women): more women receiving the candy bar, rather than 
glucose monomer, preferred the taste of the candy bar (RR 0.60, 95% CI 0.42 to 0.86) and 1-hour glucose was less with the 
candy bar. There were no differences in the other outcomes reported (maternal side effects). No infant outcomes were 
reported or any review primary outcomes. 
50 g glucose polymer drink versus 50 g glucose monomer drink (3 trials, 239 women): mean difference (MD) in gestation at 
birth was -0.80 weeks (1 trial, 100 women; 95% CI -1.69 to 0.09). Total side effects were less common with the glucose 
polymer drink (1 trial, 63 women; RR 0.21, 95% CI 0.07 to 0.59), and no clear difference in taste acceptability was reported 
(1 trial, 63 women; RR 0.99, 95% CI 0.76 to 1.29). Fewer women reported nausea following the 50 g glucose polymer drink 
compared with the 50 g glucose monomer drink (1 trial, 66 women; RR 0.29, 95% CI 0.11 to 0.78). No other measures of 
maternal morbidity or outcomes for the infant were reported. 
50 g glucose food versus 50 g glucose drink (1 trial, 30 women): women receiving glucose in their food, rather than as a 
drink, reported fewer side effects (RR 0.08, 95% CI 0.01 to 0.56). No clear difference was noted in the number of women 
requiring further testing (RR 0.14, 95% CI 0.01 to 2.55). No other measures of maternal morbidity or outcome were reported 
for the infant or review primary outcomes. 
75 g OGTT World Health Organization (WHO) criteria versus 75 g OGTT American Diabetes Association (ADA) criteria (1 
trial, 116 women): no clear differences in included outcomes were observed between women who received the 75 g OGTT 
and were diagnosed using criteria based on WHO (1999) recommendations and women who received the 75 g OGTT and 
were diagnosed using criteria recommended by the ADA (1979). Outcomes measured included diagnosis of gestational 
diabetes (RR 1.47, 95% CI 0.66 to 3.25), caesarean section (RR 1.07, 95% CI 0.85 to 1.35), macrosomia defined as > 90th 
percentile by ultrasound or birthweight equal to or exceeding 4000 g (RR 0.73, 95% CI 0.19 to 2.79), stillbirth (RR 0.49, 95% 
CI 0.02 to 11.68) and instrumental birth (RR 0.21, 95% CI 0.01 to 3.94). No other secondary outcomes were reported. 
Two-step approach (50 g oral glucose challenge test followed by selective 100 g OGTT Carpenter and Coustan criteria) 
versus one-step approach (universal 75 g OGTT ADA criteria) (1 trial, 726 women): women allocated the two-step approach 
had a lower risk of being diagnosed with GDM at 11 to 14 weeks' gestation compared to women allocated the one-step 
approach (RR 0.51, 95% CI 0.28 to 0.95). No other primary or secondary outcomes were reported. 
Authors' conclusions 
There is insufficient evidence to suggest which strategy is best for diagnosing GDM. Large randomised trials are required to 
establish the best strategy for correctly identifying women with GDM. 
Plain language summary 
Different strategies for diagnosing gestational diabetes mellitus (GDM) to improve maternal and infant health 
What is the issue? 
We aimed to evaluate and compare different ways of diagnosing gestational diabetes mellitus (GDM). We searched for all 
relevant studies in January 2017. 
Why is this important? 
Between seven and 24 pregnant women in every 100 develop GDM. GDM is when there is an inability to process 
carbohydrates properly, which leads to high blood sugar (hyperglycaemia). GDM can result in increased risks of problems 
around the time of birth for the mother and her baby. Treatment can reduce these risks, and therefore diagnosing the 
condition accurately means that treatment can be given to improve the health of mothers and their babies. 
Different testing strategies aim to diagnose GDM. We wanted to compare the different strategies, to see how they affected 
the health of women and their infants, and to assess the cost of the strategies to the healthcare service. 
What evidence did we find? 
We found seven trials. A total of 1420 women were included, in settings in Turkey, Mexico, Nigeria, New Zealand, Canada 
and the USA. Across the trials, different testing approaches and criteria were evaluated as were different diagnostic tests 
including different oral glucose tolerance test loads; a glucose drink; a candy bar and food high in glucose. Women were 
given these items to eat/drink, and this was then followed by a blood test to measure blood sugar levels and questionnaires. 
In some tests, women were required to fast from the night before. 
The main outcomes we looked for were frequency of diagnosis, incidence of caesarean section, assisted birth and vaginal 
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birth, and incidence of macrosomia in babies (larger than normal weight at birth). Other outcomes spanned a range, including 
any side effects of the tests, the mothers' preferences, and the health of the babies. 
There were a number of weaknesses among the studies: the methodology was not clear and there were important gaps in 
the data. The studies in this review do not provide enough evidence to guide clinical practice and health policy regarding 
identifying women with GDM. 
What does this mean? 
We are uncertain about which strategies to diagnose GDM are better, as we have assessed the quality of evidence as very 
low. Large randomised trials are needed to establish the best way for identifying women with GDM. 
Background 
Description of the condition 
Diabetes mellitus is a metabolic disorder that results from a defect in insulin secretion by pancreatic β-cells, insulin action or 
both. Insulin is a hormone that is secreted by specialised cells in the pancreas (pancreatic β-cells) in response to increases 
in blood glucose (blood sugar) levels. The effect of insulin is to lower blood glucose. Insulin enables most body cells to 
absorb glucose from the blood for use as fuel, for conversion to other needed molecules or for storage. Insulin is the principal 
instigator for conversion of glucose (the basic sugar used for fuel) to glycogen for internal storage in liver and muscle cells. A 
consequence of a defect that results in reduced insulin secretion or reduced ability of insulin to promote uptake of glucose 
from the blood (i.e. resistance to insulin action) is hyperglycaemia (high levels of glucose in the blood). If this becomes 
chronic (long term), disturbances in the metabolism of carbohydrate, fat and protein may occur: once levels of blood glucose 
are chronically above a specific level, diabetes is diagnosed. If diabetes is not treated, prolonged hyperglycaemia leads to 
damage and to poor function of various organs, especially eyes, kidneys, nerves, heart and blood vessels. 
Classification of diabetes mellitus 
The two most common types of diabetes are known as type 1 and type 2 diabetes mellitus (Expert 2000). 
Type 1 diabetes mellitus 
People with type 1 diabetes mellitus have absolute, or nearly absolute, insulin deficiency. This type of diabetes develops 
quickly with hyperglycaemia, rapid acidification of the blood (ketoacidosis) and death, unless treated with insulin. Type 1 
diabetes usually presents with acute onset of symptoms, including increased urination and thirst, but it can also present first 
with collapse or coma. The disease may occur at any age, but onset in childhood or adolescence is most common. Type 1 
diabetes usually results when the immune system attacks cells in the pancreas that produce insulin (autoimmune destruction 
of pancreatic β-cells). Type 1 diabetes requires life-long treatment with insulin. 
Type 2 diabetes mellitus 
People with type 2 diabetes mellitus may have resistance to insulin action or relative insulin deficiency or, more 
commonly, both. In many individuals with type 2 diabetes, problems begin with resistance to insulin action, meaning 
that higher levels of insulin are required to complete usual actions, including removal of glucose from the blood. The 
greater requirement for pancreatic β-cells to secrete insulin results in impairment of their action and ultimately in 
insulin deficiency and diabetes. The pancreas generally retains some ability to produce insulin, but it is insufficient to 
meet the body's needs. Autoimmune destruction of pancreatic β-cells does not occur, and ketoacidosis is rare. 
Insulin therapy may not be required. Type 2 diabetes mellitus usually develops slowly and is commonly 
asymptomatic, with up to 50% of adults with type 2 diabetes remaining undiagnosed (Thomas 2005; Williams 2003). The risk 
of type 2 diabetes increases with age, obesity and lack of physical activity. It can occur at any age but is relatively rare before 
the age of 30 years, however in concert with increasing obesity and reducing levels of physical activity, type 2 diabetes is 
becoming more common in young adults and is now seen in children. 
Other types of diabetes 
Less common types of diabetes mellitus include diabetes due to rare genetic disorders, congenital problems in the pancreas 
and trauma to the pancreas, as well as diabetes that occurs as a side effect of some drugs (e.g. steroids). Gestational 
diabetes is described in the section below. 
Normal pregnancy and insulin resistance 
Normal pregnancy is associated with insulin resistance similar to that found in type 2 diabetes. Physiological resistance to 
insulin action during pregnancy becomes apparent in the second trimester, and insulin sensitivity declines progressively to 
term. These changes facilitate transport of glucose across the placenta to ensure normal fetal growth and development. 
Transfer of glucose across the placenta stimulates fetal insulin secretion, and insulin acts as an essential growth hormone. 
However, if resistance to maternal insulin action becomes too pronounced, fetal hyperinsulinaemia, accelerated growth and 
possible organ damage may occur. In normal pregnancy after delivery, maternal pregnancy-associated insulin resistance 
returns rapidly to normal, and glucose tolerance usually returns to normal within six weeks of delivery. 
Gestational diabetes mellitus 
Gestational diabetes mellitus (GDM) is defined as "carbohydrate intolerance resulting in hyperglycaemia of variable 
severity with onset or first recognition during pregnancy" (Expert 2000; WHO 1999). GDM is defined in this way for 
women with undiagnosed pre-existing diabetes and for those in whom the first onset of hyperglycaemia is identified 
during pregnancy. To identify early in pregnancy women with previously undiagnosed diabetes, the International 
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Association of Diabetes and Pregnancy Study Groups (IADPSG) (Metzger 2010) recommends assessment of high-risk 
populations using glycated haemoglobin, fasting or random plasma glucose at first pregnancy booking. Other groups 
including the American Diabetes Association (ADA) (ADA 2017) and the UK National Institute for Health and Care 
Excellence (NICE 2015) also recommend early testing of high-risk groups to identify women with pre-existing diabetes. 
In the past GDM has been categorised by severity of glucose impairment, with less severe cases referred to as 
impaired glucose tolerance, and more severe cases as GDM. Hyperglycaemia is now viewed as a continuum, with 
levels along the complete distribution of glycaemia in pregnant women associated with adverse effects (HAPO Study 
Cooperative Research Group 2008). Because of this, the term 'impaired glucose tolerance' is no longer used, and all 
abnormalities of glucose intolerance in pregnancy are now referred to as 'GDM'. GDM necessarily includes women 
who first develop diabetes during pregnancy, as well as those with previously undiagnosed type 1 or 2 diabetes 
mellitus (frank or pre-existing diabetes) recognised for the first time in pregnancy, because it is impossible at the time 
of first recognition to distinguish clearly between these different diagnoses. GDM complicates between 1% and 24% of 
pregnancies (Farrar 2015a; Farrar 2016; NIH 2013) and varies with the population characteristics and the diagnostic 
glucose thresholds used. It is the most common metabolic disorder of pregnancy and is associated with increased 
maternal and perinatal morbidity (Bitó 2005; Crowther 2005; Kim 2002; Landon 2009; Schytte 2004). Reducing 
modifiable risk factors for developing GDM by eating a healthy balanced diet, achieving and maintaining a healthy 
normal weight and exercising before and throughout pregnancy may reduce the risk of development of GDM or its 
severity, but the evidence is limited (Ceysens 2006; Tieu 2017). Maternal hyperglycaemia leads to transfer of 
excessive glucose to the fetus, resulting in fetal hyperinsulinaemia. Fetal hyperinsulinaemia causes increased risk 
of fetal adiposity, macrosomia (increased birthweight) and perinatal complications (Jovanovic 2001; Kjos 1999). 
Specifically, GDM is associated with overgrowth of insulin-sensitive tissue such as adipose tissue, especially 
around the chest, shoulders and abdomen, which increases the risk of shoulder dystocia, perinatal death and birth 
trauma and makes the need for caesarean section more likely (Jovanovic 2001; Kjos 1999). Risk of hypoxaemia is 
increased in utero, and this can lead to increased risk of intra-uterine death, fetal polycythaemia (too many red 
blood cells), hyperbilirubinaemia (jaundice) and renal vein thrombosis (blood clot in the kidney vein). Evidence also 
suggests increased risk of neonatal metabolic complications, including hypoglycaemia, in babies of mothers 
experiencing GDM (Jovanovic 2001; Kjos 1999; Kostalova 2001; Pribylová 1996; Silverman 1995). Observational 
data suggest that babies of women with GDM are at increased risk of obesity (Dabelea 2000; Gillman 2003; Pettitt 1983 
) and hypertension (Akisü 1999) later in life. However, data from trials of treatment of women with mild to moderate 
GDM suggest similar adiposity in infants, regardless of their mother's group allocation (Gillman 2010; Landon 2015), data are 
few and length of follow up limited. 
Description of the intervention 
A range of recommendations and guidelines for identification of women with GDM have been published by the World 
Health Organization (WHO) (WHO 1999; WHO 2013), the International Association of Diabetes and Pregnancy 
Study Groups (IADPSG) (Metzger 2010), the American Diabetes Association (ADA 2017), the National Institute for 
Health and Clinical Excellence (NICE 2015), the Australasian Diabetes in Pregnancy Society (ADIPS 1998), the 
Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG 2014) and the 
Scottish Intercollegiate Guideline Network (Jovanovic 2004). 
The criteria for diagnosis of GDM have been debated for some time. A linear association has been noted between 
maternal glucose levels and adverse perinatal outcomes across the whole distribution of glucose levels in pregnancy ( 
HAPO Study Cooperative Research Group 2008). Thus, there is no clear threshold above which women are at high 
risk and below which they are at low risk. Criteria for diagnosis of GDM have been developed in attempts to identify 
thresholds that best predict adverse maternal and neonatal outcomes; however, lack of sufficient evidence of 
increased effectiveness in improving outcomes of one criterion over another has led to the use of different criteria, 
which are arbitrary and often are based on expert opinion. The IADPSG (Metzger 2010) has recommended revised 
thresholds (Table 1) in the light of Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) study results, which 
suggest adverse effects on fetal outcomes with glucose levels previously considered within the normal range (HAPO Study 
Cooperative Research Group 2008). The WHO (WHO 2013) and the ADA (ADA 2017) have recently endorsed the 
IADPSG criteria; however, the ADA has also endorsed the 'two-step' approach favoured by the American National 
Institutes of Health (NIH 2013). 
Tests most commonly used for diagnosis of GDM are the two-hour 75 g oral glucose tolerance test (OGTT) 
recommended by IADPSG and WHO (Metzger 2010; WHO 1999; WHO 2013) and the three-hour 100 g OGTT 
recommended by the National Institutes of Health (NIH 2013). Limitations of these tests are that they require women to 
fast from the night before (although in some studies non-fasting OGTT has been performed), to drink a glucose solution 
and to wait for two or three hours before undergoing the final blood test. Whether the drink itself has side effects is 
unclear, as is whether this might be a factor contributing to non-attendance for the test. Alternative tests that have been 
proposed for the diagnosis of GDM include glycated haemoglobin, fasting blood glucose and random blood glucose, or 
glycosuria (sugar in the urine); however, it has been suggested that these tests are not as reliable as the OGTT for 
correctly identifying women with hyperglycaemia (Scott 2002). Globally the number of women diagnosed with GDM 
is rising; factors associated with this rise include increasing rates of obesity and reduced levels of exercise (Catalano 2011; 
NICE 2015; Simmons 2011); however lowering thresholds for diagnosis will increase prevalence. Now more than ever, 
efficient and effective strategies for identifying those with GDM are needed. 
How the intervention might work 
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Oral glucose tolerance test and diagnostic criteria 
Until 2013 the World Health Organization recommended that diagnosis of GDM should be based on the same criteria 
used for non-pregnant adults (WHO 1999). The WHO recommended that with the 75 g OGTT, GDM (including impaired 
glucose tolerance) was diagnosed if the fasting plasma glucose level was greater than 7.0 mmol/L, or if the two-hour 
level was greater than 7.8 mmol/L. The UK National Institute for Health and Care Excellence (NICE) recommendations 
(NICE 2015) are based on these criteria; however, although still recommending the 75 g OGTT, NICE recommend that GDM 
should be diagnosed when either fasting plasma glucose level is equal to or greater than 5.6 mmol/L, or when the two-hour 
postload level is equal to or greater than 7.8 mmol/L. 
The National Diabetes Data Group (NDDG) recommendations for GDM diagnosis were first published by the 
American Diabetes Association in 1997 (NDDG 1997); these criteria are based on initial screening with an oral 
glucose challenge test (OGCT). This test did not require women to fast; they were given a 50 g glucose drink and had 
blood glucose checked after one hour. If the one-hour value was equal to or greater than 7.8 mmol/L, a three-hour 100 
g OGTT followed. Subsequently, the NDDG revised its recommendations, suggesting a one-step approach for high- 
risk women, using a 100 g three-hour OGTT (Expert 2000). For low-risk women, the NDDG continued to recommend a 
two-step approach with an initial 50 g glucose challenge test, followed by a 100 g three-hour OGTT for women who 
screen positive with the one-hour OGCT threshold of 7.8 mmol/L. Blood glucose levels for diagnosis of GDM on the 
three-hour test are equal to or greater than 5.3 mmol/L for fasting blood sugar, equal to or greater than 10.0 mmol/L at 
one hour, equal to or greater than 8.6 mmol/L at two hours and equal to or greater than 7.8 mmol/L at three hours (Expert 
2000). 
As discussed, the IADPSG has published guidance recommending the 75 g OGTT with lowered thresholds (compared with 
WHO 1999 criteria) in the light of HAPO study findings (Metzger 2010). Lowering the diagnostic threshold will result in the 
diagnosis of GDM in more women who have less severe hyperglycaemia. Evidence indicates that treatment of women with 
mild to moderate GDM reduces the risk of adverse perinatal outcomes; however the beneficial effects of treatment based on 
diagnosis determined using one criterion may not be the same as those of treatment based on diagnosis of GDM using 
different criteria. 
Current recommendations on the criteria for diagnosis are presented in Table 1, Table 2, Table 3 and NICE 2015. It 
is clear that the choice of test and diagnostic criteria varies both within and between countries (Kanguru 2014). 
Other tests for gestational diabetes 
The main disadvantages of the OGTT are that it is costly and unpleasant for women. Simpler, cheaper and more 
acceptable tests for initial screening and even diagnosis would be advantageous, provided they were accurate in 
identifying women with GDM or its complications or both. Random plasma glucose testing has been popular in the 
past, as it is convenient to perform. However, it fails to identify a large proportion of women who have GDM (low 
sensitivity) (McElduff 1994). Fasting plasma glucose has greater sensitivity and specificity than random glucose 
tests, but it relies on women fasting overnight, and it does not perform as well as the OGTT in identifying those 
with GDM (Perucchini 1999) because worsening insulin resistance in women with GDM may be compensated for by 
increased insulin production, which means that fasting glucose can be normal, with the early abnormality becoming apparent 
only after meals. 
Glycated haemoglobin, which reflects glucose levels over the past four weeks, does not require an overnight fast 
and needs only a single blood sample; it is increasingly recommended as a potentially valuable tool for diagnosing 
diabetes in non-pregnant people (Fonseca 2009). Use of glycated haemoglobin to diagnose GDM has not been well 
studied. In countries where fasting or random glucose or glucose challenge tests are not used to universally screen for 
GDM, the presence of glycosuria has been used as a screening method. Assessment of glycosuria is relatively cheap, 
non-invasive and acceptable to pregnant women (Hanna 2008). However, guidance from NICE 2008 and ADA 2017 no 
longer recommend its use as a screening method, instead suggesting that risk assessment (e.g. based on ethnicity, 
family history, obesity) should be used as the primary screening method in the absence of a universal blood test for 
glycaemia. Evidence indicates that glycosuria has low sensitivity for identifying hyperglycaemia/GDM determined by 
glucose tolerance testing (Scott 2002). However, its sensitivity has not been directly compared with that of risk factors 
used as the preliminary screening tool in the UK, and limited evidence suggests an association between glycosuria and 
macrosomia and risk of obesity for future children (Scott 2002). 
When to test for gestational diabetes 
Views on the most appropriate time to test women for GDM are varied. Timing is important because consideration of the 
burden on pregnant women and on healthcare service resources means that ideally the test should be performed only once 
during pregnancy. At the same time, earlier diagnosis and treatment in any woman with GDM may prevent adverse perinatal 
outcomes. Administering the test during the first trimester results in identification of women with previously undiagnosed type 
1 or type 2 diabetes, as well as those with early-onset newly occurring diabetes. Women at particularly high risk, such as 
those who had GDM in a previous pregnancy, are often offered an OGTT in the first trimester. However, as most 
physiological pregnancy-related changes in insulin sensitivity (sometimes referred to as a glucose challenge test of 
pregnancy) begin during the second trimester, testing in the first trimester may miss a large proportion of women who will 
develop GDM. For this reason it has been suggested that high-risk women who have a normal test in the first trimester will 
usually require a second test later in pregnancy. 
To avoid the need for repeated testing, most women are offered a single test in the late second trimester. This timing serves 
as a balance between testing too early (thus missing some women who do not develop gestational diabetes until after the 
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test) and testing too late (leaving little time to intervene to reduce plasma glucose and improve outcomes). 
Universal versus selective testing 
The question of whether to offer universal or selective screening remains controversial and is the topic of another 
Cochrane Review (Screening for gestational diabetes mellitus to improve maternal and infant health) (Tieu 2014). In 
the past, screening has been targeted at those with increased risk of developing the condition, for example, women 
who have had GDM in a previous pregnancy, those with a family history, women of Asian or Carribean ethnicity and 
those who are obese; however some women without risk factors may develop GDM and may remain untreated. If all 
women are offered an OGTT, more women with hyperglycaemia will be identified and more women may benefit from 
treatment (Farrar 2014). There are however no robust trial data to suggest which approach (universal or selective) 
is best for improving maternal and infant outcomes, even though treatment trials (Crowther 2005; Landon 2009) and 
reviews (Brown 2017; Farrar 2016) have demonstrated an improvement in several important perinatal outcomes when 
hyperglycaemia is reduced (a Cochrane Protocol also details a review that will provide an overview of Cochrane 
Reviews of interventions (Martis 2016)). 
Why it is important to do this review 
Accurate identification of women with GDM is important, so that treatment can be provided to reduce the risk of adverse 
outcomes associated with hyperglycaemia. The aim of this Cochrane Review was to compare alternative diagnostic tests for 
identification of GDM and to assess their association with maternal and infant outcomes and use of healthcare service 
resources. 
Objectives 
To evaluate and compare different testing strategies for diagnosis of gestational diabetes mellitus to improve maternal and 
infant health while assessing their impact on healthcare service costs. 
Methods 
Criteria for considering studies for this review 
Types of studies 
We included randomised trials that evaluated diagnostic tests carried out to diagnose gestational diabetes mellitus (GDM). 
We excluded studies that clearly were not randomised trials, as well as studies that used a quasi-random design, such as 
alternate days or date of birth, for allocation to the intervention group. Cluster or cross-over designed trials were not eligible 
for inclusion. Abstracts were eligible for inclusion if sufficient information was available for assessment and data extraction. 
Types of participants 
We included studies if they recruited pregnant women at risk of GDM. We included women if they were at low risk or high risk 
(such as women who were obese, those with a first-degree relative with diabetes, high-risk ethnic groups, high-fasting or 
random plasma glucose and previous gestational diabetes) of developing GDM. We included women with single or multiple 
gestations. 
We excluded women with diabetes diagnosed before the incident pregnancy. 
Types of interventions 
We intended to include all diagnostic tests for GDM, such as glycated haemoglobin, random and fasting blood sugar and oral 
glucose tolerance tests. We included comparisons of any testing with no testing, as well as comparisons of one form of 
testing versus another. 
We would have included comparisons of testing at different gestational ages if they had been available. 
Types of outcome measures 
We included the following outcomes in the review. We would have used primary outcomes for subgroup and sensitivity 
analyses if appropriate. 
*A number of the primary and secondary maternal and infant outcome measures were based on the core outcomes for 
Cochrane gestational diabetes reviews reached by consensus among authors of reviews for treatment of GDM. A number of 
these had been included in previous versions of this review, but some were added for this update (see Differences between 
protocol and review). 
Primary outcomes 
Maternal 
1. Mode of birth: normal, caesarean section, instrumental delivery.* 
2. Diagnosis of gestational diabetes: as assessed by need for treatment such as diet or insulin.* 
Neonatal 
1. Macrosomia: birthweight greater than 4.5 kg, or however defined in the trial.* 
Secondary outcomes 
Maternal 
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1. Induction of labour.* 
2. Side effects of testing, such as vomiting and bruising. 
3. Compliance with testing, including attendance. 
4. Need for repeat testing by the same or an alternative method. 
5. Plasma glucose (non-prespecified outcome). 
6. Perineal trauma.* 
7. Placental abruption.* 
8. Weight gain during pregnancy.* 
9. Breastfeeding (e.g. at discharge, six weeks postpartum).* 
10. Measures of costs for healthcare services, such as number of antenatal visits, admissions to hospital.* 
11. Measures of costs for women, such as time off work, need for additional child care.* 
12. Longer-term outcomes: postnatal depression, weight retention, GDM in a subsequent pregnancy, cardiovascular health 
(defined by trials, including blood pressure and hypertension), development of type 2 diabetes.* 
13. Women's views, including their preferences and measures of satisfaction.* 
14. Quality of life measures.* 
Neonatal 
1. Death: including perinatal death (stillbirth, death in the first week of life), neonatal death (death in the first 28 days of life) 
and infant death (death in the first year of life).* 
2. Birth trauma, including shoulder dystocia, nerve palsy and fracture. 
3. Preterm birth: birth before 37 completed weeks' gestation, birth before 34 weeks. 
4. Large-for-gestational age: greater than 90th centile, or however defined in the trial. 
5. Measures of neonatal morbidity, such as hypoglycaemia, hypocalcaemia, polycythaemia, respiratory distress syndrome, 
jaundice, admission to special care. 
6. Apgar score (less than seven at five minutes).* 
7. Gestational age at birth: mean. 
8. Birthweight and z-score.* 
9. Ponderal index.* 
10. Measures of adiposity.* 
11. Shoulder dystocia.* 
12. Bone fracture.* 
13. Nerve palsy.* 
14. Relavent biomarkers, e.g. cord C-peptide, cord insulin.* 
15. Longer-term outcomes: measures of growth and adiposity and neurodevelopment during childhood and educational 
achievement, diabetes, blood pressure.* 
16. Measures of costs for healthcare services, such as number of days on the neonatal unit, length of stay.* 
Search methods for identification of studies 
The following Methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. 
Electronic searches 
We searched Cochrane Pregnancy and Childbirth’s Trials Register by contacting their Information Specialist (6 January 
2017). 
The Register is a database containing over 22,000 reports of controlled trials in the field of pregnancy and childbirth. For full 
search methods used to populate Pregnancy and Childbirth’s Trials Register including the detailed search strategies for 
CENTRAL, MEDLINE, Embase and CINAHL; the list of handsearched journals and conference proceedings, and the list of 
journals reviewed via the current awareness service, please follow this link to the editorial information about the Cochrane 
Pregnancy and Childbirth in the Cochrane Library and select the ‘ Specialized Register ’ section from the options on the left 
side of the screen. 
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is maintained by their Information Specialist and contains trials 
identified from: 
1. monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL); 
2. weekly searches of MEDLINE (Ovid); 
3. weekly searches of Embase (Ovid); 
4. monthly searches of CINAHL (EBSCO); 
5. handsearches of 30 journals and the proceedings of major conferences; and 
6. weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. 
Search results are screened by two people and the full text of all relevant trial reports identified through the 
searching activities described above is reviewed. Based on the intervention described, each trial report is assigned a 
number that corresponds to a specific Pregnancy and Childbirth review topic (or topics), and is then added to the 
Register. The Information Specialist searches the Register for each review using this topic number rather than 
keywords. This results in a more specific search set which has been fully accounted for in the relevant review 
sections (Included studies; Excluded studies; Studies awaiting classification; Ongoing studies). 
In addition, we searched ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) for 
unpublished, planned and ongoing trial reports (6 January 2017) using the terms given in Appendix 1. 
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Searching other resources 
We searched the reference lists of retrieved studies. 
We did not apply any language or date restrictions. 
Data collection and analysis 
For methods used in the previous version of this review, see Farrar 2015. 
For this update, the following methods were used for assessing the 12 reports that were identified as a result of the updated 
search. 
Selection of studies 
Two review authors independently assessed for inclusion all potential studies identified as a result of the search. We 
resolved disagreements through discussion, or, if required, we consulted a third review author. 
Data extraction and management 
We designed a form for use in extracting data. For eligible studies, two review authors extracted data using the 
agreed upon form. We resolved discrepancies through discussion, or, if required, we consulted a third review author. 
We entered data into Review Manager software (RevMan 2014) and checked them for accuracy. 
When information regarding any of the above was unclear, we planned to contact authors of the original reports to request 
further details. 
Assessment of risk of bias in included studies 
Two review authors independently assessed risk of bias for each study using the criteria outlined in the Cochrane Handbook 
for Systematic Reviews of Interventions (Higgins 2011). Disagreements were resolved by discussion or by consultation with 
a third assessor. 
(1) Random sequence generation (checking for possible selection  bias) 
We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an 
assessment of whether it should produce comparable groups. 
We assessed the method as: 
low risk of bias (any truly random process, e.g. random number table; computer random number generator); 
high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number); or 
unclear risk of bias. 
(2) Allocation concealment (checking for possible selection  bias) 
We described for each included study the method used to conceal allocation to interventions before the time of assignment 
and assessed whether intervention allocation could have been foreseen in advance of or during recruitment, or changed after 
assignment. 
We assessed these methods as: 
low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); 
high risk of bias (open random allocation; unsealed or non-opaque envelopes; alternation; date of birth); or 
unclear risk of bias. 
(3.1) Blinding of participants and personnel (checking for possible performance   bias) 
We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of 
which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we 
judged that lack of blinding was unlikely to affect results. We assessed blinding separately for different outcomes or different 
classes of outcomes. 
We assessed the methods as: 
low, high or unclear risk of bias for participants; or 
low, high or unclear risk of bias for personnel. 
(3.2) Blinding of outcome assessment (checking for possible detection   bias) 
We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which 
intervention a participant received. We assessed blinding separately for different outcomes or different classes of outcomes. 
We assessed methods used to blind outcome assessment as: 
low, high or unclear risk of bias. 
(4) Incomplete outcome data (checking for possible attrition bias due to the quantity, nature and handling of 
incomplete outcome data) 
We described for each included study, and for each outcome or class of outcomes, the completeness of data, including 
attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers 
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included in the analysis at each stage (compared with the total number of randomly assigned participants), reasons for 
attrition or exclusion when reported and whether missing data were balanced across groups or were related to outcomes. 
When sufficient information was reported, or could be supplied by the trial authors, we planned to re-include missing data in 
the analyses that we undertook. 
We assessed methods as: 
low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); 
high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with 
substantial departure of intervention received from that assigned at randomisation); or 
unclear risk of bias. 
(5) Selective reporting (checking for reporting  bias) 
We described for each included study how we investigated the possibility of selective outcome reporting bias and what we 
found. 
We assessed the methods as: 
low risk of bias (when it was clear that all of the study’s prespecified outcomes and all expected outcomes of interest to 
the review had been reported); 
high risk of bias (when not all of the study’s prespecified outcomes had been reported; one or more reported primary 
outcomes were not prespecified; outcomes of interest were reported incompletely and so could not be used; study failed 
to include results of a key outcome that would have been expected to have been reported); or 
unclear risk of bias. 
(6) Other bias (checking for bias due to problems not covered by (1) to (5)   above) 
We described for each included study important concerns that we had about other possible sources of bias. 
(7) Overall risk of bias 
We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the Cochrane 
Handbook for Systematic Reviews of Interventions (Higgins 2011). With reference to (1) to (6) above, we planned to assess 
the likely magnitude and direction of bias, and whether we considered it likely to impact study findings. In future updates, we 
will explore the impact of the level of bias by undertaking sensitivity analyses (see Sensitivity analysis). 
Assessment of the quality of the evidence using the GRADE approach 
For this update the quality of the evidence was assessed using the GRADE approach as outlined in the GRADE handbook in 
order to assess the quality of the body of evidence relating to the following outcomes for the main comparisons. 
We assessed the quality of the body of evidence as related to the following outcomes for the comparison of 75 g oral glucose 
tolerance testing (OGTT) versus 100 g GTT. 
1. Diagnosis of gestational diabetes.* 
2. Caesarean section.* 
3. Macrosomia > 4.5 kg, or however defined in the trial. 
4. Long-term type 2 diabetes maternal.* 
5. Long-term type 2 diabetes infant.* 
6. Economic costs. 
Some of the outcomes above* relate to outcomes from GRADE core outcomes for Cochrane gestational diabetes reviews 
reached by consensus among authors of reviews for treatment of GDM. 
We used GRADEpro Guideline Development Tool to import data from Review Manager 5.3 (RevMan 2014) to create a 
'Summary of findings' table. A summary of the intervention effect and a measure of quality for each of the above outcomes 
was produced using the GRADE approach. The GRADE approach uses five considerations (study limitations, consistency of 
effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The 
evidence can be downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, 
depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or 
potential publication bias. 
Measures of treatment effect 
Dichotomous data 
For dichotomous data, we presented results as summary risk ratios (RRs) with 95% confidence intervals (CIs). 
Continuous data 
We used mean differences (MDs) when outcomes were measured in the same way between trials. We planned to use the 
standardised mean differences (SMDs) to combine trials that measured the same outcome but used different methods. 
SMDs were not used in this update. 
Unit of analysis issues 
Cluster-randomised trials 
Cluster-randomised trials were not eligible for inclusion. 
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Cross-over trials 
Cross-over trials were not eligible for inclusion. 
Multi-armed trials 
When a multi-armed trial was included, we recorded and included in the review all outcome data as two-arm 
comparisons. We included the data for different arms in independent two-arm comparisons in separate meta- 
analyses. When the control group was shared by the two study arms, we divided the control group between relevant 
subgroup categories to avoid double counting of participants (for dichotomous data we divided the events and the 
total population, and for continuous data we assumed the same mean and standard deviation (SD) but divided the 
total population). In future updates, when we cannot include the data in separate comparisons, we will combine them 
to create a single pair-wise comparison (Higgins 2011). We will describe details in the Characteristics of included studies 
tables. 
Other unit of analysis issues 
One trial included 35 women with twin pregnancies (Mexico 2011). Effects on outcomes of different strategies for diagnosing 
GDM may differ between singleton and multiple pregnancies; therefore caution should be taken when the results of analyses 
that include data from this trial are considered. 
Dealing with missing data 
For included studies, levels of attrition were noted. In future updates, if more eligible studies are included, the impact of 
including studies with high levels of missing data in the overall assessment of treatment effect will be explored by performing 
sensitivity analysis. 
For all outcomes, analyses were carried out, as far as possible, on an intention-to-treat basis (i.e. we attempted to include in 
the analyses all participants randomly assigned to each group). The denominator for each outcome in each trial was the 
number randomly assigned minus any participants whose outcomes were known to be missing. 
Assessment of heterogeneity 
We assessed statistical heterogeneity in each meta-analysis using Tau², I² and Chi² statistics and regarded heterogeneity as 
substantial if I² was greater than 30% and either Tau² was greater than zero or the P value was low (< 0.10) in the Chi² test 
for heterogeneity. If we identified substantial heterogeneity (> 30%), we planned to explore this by performing prespecified 
subgroup analysis. 
Assessment of reporting biases 
In future updates, if 10 or more studies are included in the meta-analysis, we will investigate reporting biases (such as 
publication bias) by using funnel plots. We will assess funnel plot asymmetry visually. If asymmetry is suggested by visual 
assessment, we will perform exploratory analyses to investigate this. 
Data synthesis 
We carried out statistical analysis using Review Manager software (RevMan 2014). We used fixed-effect meta-analysis for 
combining data when it was reasonable to assume that studies were estimating the same underlying treatment effect (i.e. 
when trials were examining the same intervention and the trials’ populations and methods were judged sufficiently similar). 
If clinical heterogeneity had been sufficient to suggest that underlying treatment effects differed between trials, or if 
substantial statistical heterogeneity was detected, we planned to use random-effects meta-analysis to produce an overall 
summary if an average treatment effect across trials was considered clinically meaningful. In this update, random-effects 
meta-analysis was not performed. In future updates, if we conduct random-effects analysis, this will be treated as the 
average range of possible treatment effects, and we will discuss the clinical implications of differing treatment effects 
between trials. If the average treatment effect is not clinically meaningful, we will not combine trials. If we use random-effects 
analyses, results will be presented as the average treatment effect with 95% CIs, along with estimates of Tau² and I². 
Subgroup analysis and investigation of heterogeneity 
It was not possible to carry out any subgroup analyses because data were insufficient. In future updates, if we identify 
substantial heterogeneity, we will investigate this by using subgroup analyses and sensitivity analyses. We will consider 
whether an overall summary is meaningful, and if it is, we will use random-effects analysis to produce it. 
We will carry out the following subgroup analyses in future updates. 
1. Ethnicity. 
2. Body mass index (underweight, normal weight, overweight and obese). 
The following outcomes will be used in subgroup analyses in future updates. 
1. Mode of birth: normal, caesarean section, instrumental delivery. 
2. Diagnosis of gestational diabetes - as assessed by need for treatment, such as diet or insulin. 
3. Macrosomia: birthweight greater than 4.5 kg, or however defined in the trial. 
We will assess subgroup differences by performing interaction tests available within RevMan (RevMan 2014). We will report 
the results of subgroup analyses by quoting the Chi² statistic and the P value, and those of the interaction test by providing 
the I² value. 
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Sensitivity analysis 
If relevant to future updates, we will carry out sensitivity analyses to explore the effects of trial quality assessed by 
concealment of allocation, high attrition rates or both, with poor quality studies excluded from the analyses to permit 
assessment of whether this makes any difference in the overall result. This was not possible in this update because included 
data were insufficient. 
Results 
Description of studies 
Results of the search 
See Figure 1. 
The updated search in January 2017 search retrieved 12 potentially eligible trial reports. One trial was included (Turkey 
2014). One trial is awaiting classification (China 2013). One trial was excluded (USA 2015) and a further five trial 
reports were added to a previously excluded trial (Ireland 2014a). Two trials (four reports) are ongoing (Ireland 2014b; USA 
2014). 
Included studies 
We included seven trials with 1420 women. One new trial including 736 women was included in this update (Turkey 2014 
). One trial (Nigeria 2004) compared 75 g with 100 g oral glucose tolerance test (OGTT) using World Health 
Organization (WHO) and National Diabetes Data Group (NDDG) criteria for diagnosis of gestational diabetes mellitus 
(GDM) (NDDG 1997). One trial (USA 1994) compared a candy bar and glucose polymer and glucose monomer 
drinks. Glucose monomer, referred to as d-glucose, was defined as the 'standard' intervention; therefore, data related 
to this group were divided for comparison with the two remaining intervention groups. One trial compared 50 g 
glucose food with a 50 g glucose drink (Mexico 2003). Another trial (Mexico 2011) included three comparison groups: 75 
g OGTT using WHO criteria; 75 g OGTT using American Diabetes Association (ADA) criteria; and 100 g OGTT using 
ADA criteria. Non-randomised participants were included in the 100 g OGTT group (ADA criteria); therefore data for this 
group were not included in this review. Two trials compared a glucose polymer drink with a glucose monomer drink (New 
Zealand 1985; USA 1992). One trial compared the two-step (50 g OGCT and 100 g OGTT, diagnosis based on the 
Carpenter and Coustan criteria) with the one-step (75 g OGTT, diagnosis based on the WHO (1999) criteria) 
approach (Turkey 2014). 
Three trials (Mexico 2011; Nigeria 2004; Turkey 2014) reported maternal primary outcomes while only one trial (Mexico 
2011) reported neonatal primary outcomes. Another trial (New Zealand 1985) reported macrosomia, but only for 
women who were subsequently diagnosed with GDM rather than for all women who were randomly assigned. The 
remaining three trials (Mexico 2003; USA 1992; USA 1994) only reported secondary outcomes. Infant outcomes were 
reported in three trials (Mexico 2011; New Zealand 1985; Nigeria 2004). Mexico 2011 reported macrosomia and stillbirth. 
Nigeria 2004 reported difference in mean birthweight, which was not one of our prespecified outcomes. The duration 
of follow-up for all trials was short; lasting only one hour in three trials (Mexico 2003; USA 1992; USA 1994) and three 
hours in two trials (New Zealand 1985; Nigeria 2004). In Turkey 2014 there was no follow up because of the limited data that 
could be included, in Mexico 2011 follow up lasted up until birth. 
Excluded studies 
We excluded 30 trials, of which 15 used cross-over designs (Austria 1994; Austria 1998; Germany 2004; Hong Kong 1993; 
Iran 2007; Iran 2008; New Zealand 1984a; New Zealand 1984b; Singapore 1992; Thailand 2003; Tunisia 2001; USA 1993a; 
USA 1993b; USA 1995; USA 1999); five did not randomise allocation (China 1995; China 1995a; Greece 2004; Thailand 
1995; USA 1993c); two used quasi-randomisation techniques (USA 1989; USA 1991); two did not meet our 
participant inclusion criteria (known non-GDM and known GDM respectively at recruitment) (Thailand 2008; USA 2001 
); two did not provide the correct intervention (Canada 1999; Ireland 2000); two did not report outcomes in a form that 
allowed inclusion in the analyses (Canada 2005; USA 1995a); and one did not report sufficient data (USA 2015). 
Risk of bias in included studies 
All trials were relatively small and had several aspects of unclear quality with few outcomes reported. See Figure 2 and 
Figure 3 for a summary of risk of bias assessments. 
Allocation (selection bias) 
Two trials ( Turkey 2014; USA 1992) were judged as low risk of bias for sequence generation as they used computer 
generated random numbers and a random number table. It was unclear in the remaining five trials (Mexico 2003; Mexico 
2011; New Zealand 1985; Nigeria 2004; USA 1994). All of the trials were judged as unclear risk of bias for allocation 
concealment. 
Blinding (performance bias and detection bias) 
Two trials (New Zealand 1985; Nigeria 2004) were judged low risk for performance bias and detection bias: blinding 
of personnel and participants was not reported but this was possible because the tests consisted of glucose drinks 
that appeared to be identical and the outcomes were objective, for example, plasma glucose value and of birthweight, 
and would not have been affected by knowledge of treatment groups. Two trials were assessed as being at high risk 
for performance bias (Mexico 2003; USA 1994) and unclear for detection bias: blinding of participants and personnel 
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was not reported but the reporting of side effects may have been influenced by knowledge of the treatment and it is 
unclear whether knowledge of side effects would have influenced outcome assessment. Two trials (Mexico 2011; USA 1992 
) were judged as unclear risk for performance bias: in one (Mexico 2011), blinding of personnel and participants was 
not reported but would have been possible because the tests consisted of glucose drinks that could have appeared to 
be identical. Blood glucose levels, birthweight and ruptured membranes would not have been affected by knowledge 
of treatment groups, but outcomes such as caesarean birth may have been affected. Outcome assessment was not 
reported and so was also assessed as being unclear (Mexico 2011). In the other trial, (USA 1992), it was described as 
double blind, which is possible as test drinks may have appeared identical, however, the outcome of side effects could have 
been affected by knowledge of treatment groups, although the plasma glucose value would not have been affected. For 
outcome assessment, USA 1992, was assessed as being at low risk, because side effects were self-reported on a 
questionnaire and thus were not subject to assessor bias and plasma glucose values would not have been affected by lack 
of blinding on the part of assessors. The final trial, Turkey 2014, was assessed as being at unclear risk for both performance 
and detection bias: the tests were clearly different, but the outcome of GDM diagnosis is a biochemical assessment and so 
this would not have been influenced by lack of blinding; outcome assessment was not reported. 
Incomplete outcome data (attrition bias) 
Four trials (Mexico 2003; New Zealand 1985; Turkey 2014; USA 1992) were judged as low risk of attrition bias with 
no loss to follow-up described. The three remaining trials (Mexico 2011; Nigeria 2004; USA 1994) were judged as 
having high risk of attrition bias: loss to follow-up was reported in up to 11% of participants in (USA 1994); loss of 
follow-up was reported up to 15% in another (Nigeria 2004); and seven women were excluded because they could not 
tolerate the 75 g diagnostic test given in Mexico 2011, suggesting that this trial did not analyse data using intention-to-treat 
methodology. 
Selective reporting (reporting bias) 
All seven included trials (Mexico 2003; Mexico 2011; New Zealand 1985; Nigeria 2004; Turkey 2014; USA 1992; USA 1994) 
were judged as low risk for reporting bias, however it is possible that not all outcomes were reported as no protocols were 
available. 
Other potential sources of bias 
Two trials (New Zealand 1985; Nigeria 2004) were judged as having low risk of bias, with no other potential sources 
of bias identified. Another three trials (Mexico 2011; Turkey 2014; USA 1994) were assessed as being at high risk of bias for 
this domain. Turkey 2014 only reported characteristics of women included in their final analysis 486/726; therefore the 
effectiveness of the randomisation process could not be assessed. Significant group differences were reported with respect 
to age and parity in USA 1994, which may be due to inadequate randomisation or small sample size. Inclusion of non- 
randomised participants and unclear reporting of methods and outcomes suggest potential for 'other' bias in Mexico 2011. 
It was unclear in the remaining two trials (Mexico 2003; USA 1994). 
Effects of interventions 
Comparison 1. 75 g OGTT versus 100 g OGTT 
We included one trial with 248 women in this comparison. 
Primary outcomes 
Diagnosis of gestational diabetes 
Use of a 75 g OGTT rather than a 100 g OGTT was associated with increased risk of being diagnosed with GDM (RR 2.55, 
95% CI 0.96 to 6.75; 1 trial, 248 women; Analysis 1.1; very low-quality evidence). No other primary outcomes for mother or 
baby were reported in this trial. 
Secondary outcomes 
No clear differences in blood glucose levels at one hour (MD -0.11, 90% CI -0.44 to 0.22; 1 trial, 248 women; Analysis 1.2) 
and at two hours (MD -0.31, 90% CI -0.64 to 0.02; 1 trial, 248 women; Analysis 1.2) were observed between groups. At three 
hours women allocated 75 g OGTT had lower blood glucose than those allocated a 100 g test (MD -1.08 mmol/L, 95% CI 
-1.55 to -0.61; 1 trial, 248 women; Analysis 1.2). No other maternal nor neonatal outcomes were reported. 
Comparison 2. 50 g glucose polymer drink versus 50 g glucose monomer drink 
We included three trials with 239 women in this comparison. 
Primary outcomes 
No primary outcomes were reported. 
Secondary outcomes 
Two trials with 131 women reported side effects. Total reported side effects were less common with the glucose polymer (RR 
0.21, 95% CI 0.07 to 0.59; 1 trial, 63 women; Analysis 2.1). Side effects reported were bloating, pain, nausea, headache, 
dizziness, tiredness and vomiting. Each reported side effect tended to be less common for women given the glucose polymer 
drink, with the exception of vomiting, which was not reported by either group. Nausea (RR 0.29, 95% CI 0.11 to 0.78; 1 trial, 
66 women) was reported more often by women given the glucose monomer drink. There was no clear difference between 
groups for headache (RR 0.20, 95% CI 0.02 to 1.62; 1 trial, 66 women); bloating (RR 0.41, 95% CI 0.15 to 1.12; 2 trials, 131 
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women; I² = 49%); dizziness (RR 0.40, 95% CI 0.08 to 1.92; 1 trial, 66 women); tiredness (RR 1.33, 95% CI 0.32 to 5.50; 1 
trial, 66 women); pain (RR 0.14, 95% CI 0.02 to 1.12; 2 trials,129 women; I² = 0%); and taste acceptability (RR 1.05, 95% CI 
0.37 to 3.00; 1 trial, 63 women). No other maternal outcomes were reported (see Analysis 2.1). 
Three trials (239 women) reported one-hour glucose levels (MD -0.27 mmol/L, 95% CI -0.56 to 0.03), and one trial reported 
two-hour (MD -0.40 mmol/L, 95% CI -0.85 to 0.05; 100 women) and three-hour (MD 0.00 mmol/L, 95% CI -0.45 to 0.45; 100 
women) glucose levels. No clear difference in glucose levels was noted between the groups (see Analysis 2.2). 
Infants in the glucose polymer group had lower gestational age at birth compared with those in the glucose monomer group 
(MD -0.80 weeks, 95% CI -1.69 to 0.09; 1 trial, 100 women; Analysis 2.3), but it should be noted that the CIs ranged from a 
1.69-week reduction to a 0.09-week increase. 
No outcomes were reported for the baby. 
Comparison 3. Candy bar versus 50 g glucose monomer drink 
We included one trial with 60 women in this comparison. 
Primary outcomes 
No primary outcomes were reported. 
Secondary outcomes 
Reported side effects were pain, bloating and total side effects. No difference in total side effects was noted between women 
receiving the candy bar and women receiving the glucose monomer drink (RR 1.03, 95% CI 0.58 to 1.82). There was also no 
clear difference between the groups for pain (RR 0.17, 95% CI 0.01 to 3.91; 1 trial, 58 women), and bloating (RR 1.08, 95% 
CI 0.21 to 5.40; 1 trial, 60 participants). Nevertheless, there was evidence to suggest that women preferred the taste of the 
candy bar (RR 0.60, 95% CI 0.42 to 0.86; 1 trial, 59 women; Analysis 3.1). 
The one-hour serum glucose level was lower for women taking the candy bar than for those taking a glucose monomer drink 
(MD -1.0 mmol/L, 95% CI -1.13 to -0.87; 1 trial, 59 women; Analysis 3.2). It should be noted that the authors report 'serum' 
glucose as opposed to 'plasma' glucose (our prespecified outcome) although glucose levels are likely to be similar using 
either plasma or serum glucose it would be incorrect to report them as one and the same. No other maternal outcomes were 
reported. 
No outcomes were reported for the baby. 
Comparison 4. 50 g glucose food versus 50 g glucose drink 
We included one trial with 30 women in this comparison. 
Primary outcomes 
No primary outcomes were reported. 
Secondary outcomes 
Women receiving glucose in their food, rather than as a drink, reported fewer side effects (RR 0.08, 95% CI 0.01 to 0.56; 1 
trial, 30 women; Analysis 4.1). No difference was reported in the number of women requiring repeat testing by the same or 
an alternative method (RR 0.14, 95% CI 0.01 to 2.55; 1 trial, 30 women; Analysis 4.2). 
No other maternal outcomes nor neonatal outcomes were reported. 
Comparison 5. 75 g OGTT (WHO criteria) versus 75 g OGTT (ADA criteria) 
We included one trial with 116 women in this comparison. No differences between treatment groups were observed for any 
outcome. 
Primary outcomes 
Birth outcomes for women were similar among treatment groups for caesarean birth (RR 1.07, 95% CI 0.85 to 1.35; Analysis 
5.1) and instrumental birth (RR 0.21, 95% CI 0.01 to 3.94; Analysis 5.2). Diagnosis of gestational diabetes (RR 1.47, 95% CI 
0.66 to 3.25; Analysis 5.3) and macrosomia (> 90th percentile by ultrasound or birthweight ≥ 4000 g) (RR 0.73, 95% CI 0.19 
to 2.79; Analysis 5.4) were also similar between treatment groups. 
Secondary outcomes 
No differences between treatment groups were reported for the infant outcome stillbirth (RR 0.49, 95% CI 0.02 to 11.68; 
Analysis 5.5). 
Two-step approach (50 g oral glucose challenge test (OGCT) followed by selective 100 g OGCT, Carpenter 
and Coustan criteria) versus one-step approach (universal 75 g OGTT, ADA criteria) 
Primary outcomes 
We included one trial with 726 women. Risk of being diagnosed with GDM at 11 to 14 weeks' gestation (RR 0.51, 
95% CI 0.28 to 0.95) was lower with the two-step compared to the one-step approach. No other outcomes were 
reported (Analysis 6.1). 
Secondary outcomes 
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No secondary outcomes were reported. 
Discussion 
Five included trials compared different ways of giving a glucose load (Mexico 2003; New Zealand 1985; Nigeria 2004; USA 
1992; USA 1994), one compared outcomes when two different criteria were used to diagnose gestational diabetes 
mellitus (GDM) with the 75 g oral glucose tolerance test (OGTT) (Mexico 2011) and one compared the two and one- 
step approaches (Turkey 2014). None evaluated the more important question of when is the best time during pregnancy to 
test women for GDM, and none compared the standard OGTT, which requires women to fast overnight, with a test that does 
not require an overnight fast. No comprehensive comparisons examined healthcare service costs associated with different 
test strategies. We excluded Canada 2005 from this review because the data were reported as percentages only; however, 
Meltzer 2010b used a subset of participants from Canada 2005 to conduct a simple analysis of laboratory and transportation 
costs associated with carrying out the one-step or the two-step method and with using the 75 g or 100 g OGTT. The two-step 
approach was reported to be less expensive than the one-step approach. 
Summary of main results 
We included seven small trials that included a total of 1420 women. Primary outcomes reported were diagnosis of 
GDM, macrosomia, caesarean section and instrumental birth (Mexico 2011; Nigeria 2004 Turkey 2014). Nigeria 2004 
compared use of a 75 g OGTT versus a 100 g OGTT and reported results for the diagnosis of GDM. Women who received 
the 75 g OGTT had greater relative risk of being diagnosed with GDM. Although the point estimate suggests a two-fold to 
three-fold increase in relative risk, the CIs are wide and ranged from a 6.75 increase to a 0.04 reduction. Furthermore, 
evidence for this outcome was assessed as very low-quality. Mexico 2011 compared use of the 75 g OGTT (WHO criteria) 
versus the 75 g OGTT (ADA criteria) and reported results for the diagnosis of GDM, macrosomia, caesarean section and 
instrumental birth. None of these results showed differences between treatment groups. No trial has yet evaluated the 
effectiveness of the International Association of Diabetes and Pregnancy Study Groups diagnostic criteria for reducing the 
risk of adverse perinatal outcomes; the 75 g OGTT is recommended (GDM diagnosis is made if any one glucose level is 
equal to or greater than fasting 5.1 mmol/L, one hour post load 10.0 mmol/L or two hours post load 8.5 mmol/L). Turkey 2014 
compared the two-step (50 g OGCT followed by 100 g OGTT, Carpenter and Coustan criteria) with the one-step (75 g 
OGTT, ADA criteria) approach. This trial was conducted to evaluate the performance characteristics of the two approaches, 
no maternal or infant outcomes were reported with the exception of GDM diagnosis (other outcomes included sensitivity and 
specificity and positive and negative predicted value). Results suggest a lower risk of being diagnosed with GDM if the two- 
step compared to the one-step approach was used (RR 0.51, 95% CI 0.28 to 0.95). 
Overall, few secondary outcomes were reported. However, trials assessing ways of giving a glucose load that are likely to be 
more palatable to women tended to report that these alternatives were associated with fewer side effects and that women 
preferred their taste. 
Overall completeness and applicability of evidence 
Data in this review are incomplete in two key areas. The first is that no trials have evaluated the important questions, such as 
when is the best time during pregnancy to test women for GDM, and whether women need to fast overnight before testing. 
The second is that trials included in this review have not reported data for most of the substantive outcomes. Data are 
therefore missing for most of the prespecified primary and secondary outcomes. Two trials reported outcomes for infants, but 
these data were incomplete or were not related to one of our prespecified outcomes and so could not be included in the 
review. 
Studies were conducted in various countries, including Mexico, New Zealand, Nigeria, Turkey and the USA, increasing the 
generalisability of the findings. Most women were between 24 and 28 weeks' gestation, one trial however reported GDM 
diagnosis at 11 to 14 weeks' gestation. Some women were classed as being at 'high' risk for GDM, but risk for most was 
unclear. 
Quality of the evidence 
None of the trials in this review adequately reported all aspects of the methods used and so the risk of bias of the included 
studies is generally unclear or high. Five trials were judged as having high risk of bias in at least one domain. Only two of the 
seven trials reported sequence generation, and concealment of allocation was not clearly reported in any of the trials. 
Blinding of the participant and the clinician to the intervention would not have been possible for most of these trials, but it 
would have been possible for the glucose monomer and polymer drinks. In three trials blinding of outcome assessors would 
have been possible. Losses to follow-up were variable, and in studies that asked women to complete questionnaires, data 
are missing for women who did not return the completed questionnaire. One trial suffered a 30% loss of participants which is 
considerable particularly given the women were still pregnant and therefore still receiving care, reasons for these losses were 
not provided by the authors. One trial included women with twin pregnancies, but did not report whether investigators 
accounted for this in their analyses, or to how many and to which comparison groups the twin pregnancies were 
allocated. Three trials reported that some women did not complete testing because of side effects. 
We prespecified six outcomes to be assessed for quality using the GRADE (Grades of Recommendation, Assessment, 
Development and Evaluation) method. Data for assessment were provided for only one outcome - diagnosis of gestational 
diabetes for the comparison of 75 g OGTT versus 100 g OGTT and the evidence was considered to be of very low quality 
when assessed by GRADE due to design limitations, wide confidence intervals crossing the line of no effect, few events and 
small sample size. No data were reported for the following additional outcomes prespecified for assessment in GRADE: 
caesarean section, macrosomia > 4.5 kg, long-term type 2 diabetes maternal, long-term type 2 diabetes infant and economic 
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Potential biases in the review process 
We conducted an extensive search, but it remains possible that studies may have been missed. If we identify any such 
studies in future searches, we will assess them for potential inclusion in this review. 
As the quality of the included trials is unclear, the potential for bias is present. Another significant source of potential bias is 
missing outcome data. Therefore study results should be interpreted with caution. 
Agreements and disagreements with other studies or reviews 
To our knowledge one other review has been published to evaluate methods of diagnosing gestational diabetes mellitus 
(Scott 2002). This review included primary studies that were unrestricted by study design and therefore were more 
susceptible to bias. Review authors concluded that high-quality evidence is insufficient to guide practice, and that 
randomised trials of alternative screening and diagnostic tests should be undertaken. 
A recently published report funded by the UK National Institute for Health Research, Health Technology Assessment 
programme provides a comprehensive assessment of evidence related to the identification and treatment of 
hyperglycaemia in pregnancy, including analyses of individual participant data from two large UK based contemporary 
cohorts, systematic reviews and a comprehensive economic analysis (Farrar 2016). Findings reported include differences in 
glucose and associated maternal and infant outcome prevalence by ethnic group, highlighting the need for further population- 
based epidemiological surveys that include ethnically diverse women. The report concluded that given the lack of longer-term 
evidence of effectiveness (and using the NICE recommended QALY threshold), the identification and treatment of 
hyperglycaemia in pregnancy is not cost-effective. 
Authors' conclusions 
Implications for practice 
The incidence of gestational diabetes mellitus (GDM) is rising throughout the world. Evidence suggests that 
treatment of women with GDM improves some short-term perinatal outcomes (Crowther 2005; Landon 2009) 
strengthening the rationale for identifying women who have GDM. Strategies to diagnose GDM therefore need to be 
accurate, acceptable to women and affordable and demonstrate a clinically relevant reduction in risk of important 
adverse maternal and infant outcomes. Given that the International Association of Diabetes and Pregnancy Study 
Group's (IADPSG) recommended criteria aim to reduce the risk of infant obesity through its association with 
macrosomia, the challenge is not only to report short term outcomes, but to conduct adequate follow up so that 
longer-term health can be assessed, though limited evidence suggest offspring adiposity at five to 10 years is similar 
irrespective of whether mother was treated or not treated (Gillman 2010; Landon 2015), this does not exclude the possibility 
however that an effect may be seen as these infants age. 
There is limited evidence to suggest which approach is superior to diagnose GDM, this includes those strategies 
(universal/selective) tests (glucose loads) and criteria (Carpenter and Coustan, NDDG, NICE, IADPSG) that have 
been used in clinical practise for several decades (Carpenter 1982) or are more recent additions (IADPSG 2010). 
Until well-designed trials have been conducted that evaluate different approaches to diagnosing GDM, clinicians and those 
commissioning services should consider the available evidence and base their decisions on this, their population and their 
resources. 
Implications for research 
Large randomised trials are required to establish the best strategy for correctly identifying women with GDM. Information on 
when women should be tested is needed, as is information on the optimal criteria such as the IADPSG 2010 and WHO 1999 
criteria and tests such as 75 g and 100 g oral glucose tolerance tests or alternative glucose loads (jelly beans, etc). 
Studies should be of high quality and should report methods clearly. Outcomes should include measures of morbidity 
and mortality for the baby, as well as substantive outcomes for the mother. Follow-up of women and their offspring 
should be conducted for several years (Meltzer 2010a) or ideally until offspring are adults. 
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Differences between protocol and review 
*A number of the primary and secondary maternal and infant outcome measures are based on the core outcomes for 
Cochrane gestational diabetes reviews reached by consensus between the review authors of reviews for treatment of GDM. 
A number of these were added as secondary outcomes for this update and are labelled as non-prespecified in the following 
list. 
Maternal 
1. Perineal trauma (non-prespecified outcome).* 
2. Placental abruption (non-prespecified outcome).* 
3. Weight gain during pregnancy (non-prespecified outcome).* 
4. Breastfeeding (e.g. at discharge, six weeks postpartum) (non-prespecified outcome).* 
Neonatal 
1. Apgar score (less than seven at five minutes) (non-prespecified outcome).* 
2. Birthweight and z-score (non-prespecified outcome).* 
3. Ponderal index (non-prespecified outcome).* 
4. Measures of adiposity (non-prespecified outcome).* 
5. Shoulder dystocia (non-prespecified outcome).* 
6. Bone fracture (non-prespecified outcome).* 
7. Nerve palsy (non-prespecified outcome).* 
8. Relavent biomarkers, e.g. cord C-peptide, cord insulin (non-prespecified outcome).* 
The outcome plasma glucose was not originally specified in the protocol but was added in the first version of this review. 
Methods have been updated to current Cochrane Pregnancy and Childbirth Group standard text, and a 'Summary of findings' 
table has been incorporated. 
Published notes 
Characteristics of studies 
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Methods 'Randomly assigned'; no further information was given. 
No losses to follow-up were reported. 
Participants 30 women at 24 to 28 weeks' gestation, defined as 'high risk'; no further information 
was reported regarding criteria for being high-risk or criteria for GDM diagnosis. 
Settings: Hospital, Mexico. 
Interventions Experimental: 15 women; diet of carbohydrates, proteins and fats including 50 g of 
glucose. 
Control: 15 women; 50 g of glucose in solution. 
Outcomes Women: side effects (nausea, sickness, migraine, diarrhoea), screen positive 1-hour 
serum glucose > 140 mg/dL. 
Babies: none reported. 
Notes Women with serum glucose above 140 mg/dL were offered further testing. 
Study dates: not reported. 
Funding sources: not reported; declarations of interest: not reported. 




Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk 'Randomly assigned' is stated in the abstract. No further information is 
given in the main text. 
Allocation concealment (selection 
bias) 
Unclear risk Concealment of allocation was not reported. 
Incomplete outcome data (attrition 
bias) 
Low risk No losses to follow-up were reported. 
Selective reporting (reporting bias) Low risk Prespecified outcomes of side effects and serum glucose > 140 mg/dL at 
1 hour were reported. 
Other bias Unclear risk No table of participants' baseline characteristics was provided to permit 
judgement of the effectiveness of randomisation. 
Blinding of participants and 
personnel (performance bias) 
High risk Blinding of participants and personnel was not reported. Reporting of side 
effects may be influenced by knowledge of treatment. 
Blinding of outcome assessment 
(detection bias) 
Unclear risk Blinding of outcome assessment was not reported. Unclear risk because 
reporting of side effects may have been influenced by knowledge of 
treatment, but the outcome of serum glucose > 140 mg/dL would not 
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Methods 'Randomised by a computer programme'; no other information was given (see notes 
below and risk of bias table). 
Participants 386 women at 12 to 28 weeks' gestation were attending for care at the National 
Institute of Perinatology Isidro Espinosa de los Reyes, Mexico, 116 of whom were 
included in this review. 
Settings: National Institute of Perinatology Isidro Espinosa de los Reyes, Mexico. 
Interventions 75 g OGTT WHO 1999 criteria, 75 g OGTT ADA 2010 criteria and 100 g OGTT 
O'Sullivan 1973 criteria. 
Outcomes GDM diagnosis, stillbirth, macrosomia, threat of preterm birth, caesarean and 
instrumental birth, pregnancy-induced hypertension, preterm rupture of membranes, 
oligohydramnios, polyhydramnios. 
Notes Non-randomised participants included in the group were allocated 100 g OGTT with 
ADA criteria; therefore this group was not included in any analysis. 
Study dates: 1 June 2006 to 1 September 2006. 
Funding sources: not reported; declarations of interest: not reported. 




Support for judgement 




'Randomised by a computer programme'; no other information was given. 




Concealment of allocation was not reported. 
Incomplete outcome data (attrition 
bias) 
High risk 7/54 (13%) participants allocated 75 g OGTT were unable to complete and 
were not followed up and included in the analysis. 
Selective reporting (reporting bias) Low risk All prespecified outcomes seem to have been reported. 
Other bias High risk The numbers for this trial are unclear. It appears that women > 28 weeks 
who were not screened or randomly assigned were included in the 100 g 
OGTT group. Inclusion of non-randomised participants in 1 of the groups; 
uneven numbers in the remaining groups, possibly due to the fact that 
study authors failed to use an intention-to-treat design (see notes above 
regarding loss of participants due to lack of completion of the test); 
possible 'double' counting of participants in the screened tables; and lack 
of clarity surrounding the study design suggest that extreme caution should 
be exercised when results from this trial are interpreted. 35 twin 
pregnancies were included; however group allocation was not reported, so 
they may or may not be included in the comparison groups described in 
this review. We have used data from 2 groups including 116 randomly 
assigned women. 
Blinding of participants and 
personnel (performance bias) 
Unclear 
risk 
Blinding of personnel and participants is not reported but is possible 
because the tests consisted of glucose drinks and could have appeared to 
be identical. Blood glucose levels, birthweight and ruptured membranes 
would not have been affected by knowledge of treatment groups, but 
outcomes such as caesarean birth may have been affected. 




Blinding of outcome assessors was not reported. 
New Zealand 1985 
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Methods 'Randomised into two groups'; no further information was given. 
No losses to follow-up were reported. 
Participants 100 women at 28 weeks' gestation without pre-existing diabetes were given a 100 g 
non-fasting OGTT. NDDG 1979 criteria were used to diagnose GDM. 
Settings: prenatal clinics, National Women's Hospital, Mexico. 
Interventions Experimental: 52 women; 100 g glucose polymer screening test was given before a 
100 g OGTT glucose polymer tolerance test was given. 
Control: 48 women; 100 g glucose screening test was given before a 100 g GTT was 
given. 
Outcomes Women: 1-, 2- and 3-hour blood glucose at GTT. 
Babies: gestation at birth, mean birthweight. 
Notes Mean birthweight was reported: 3427 g (SD 566) for polymer screening group vs 3280 
g (SD 739) for glucose screening group. 
Report includes a case series of a further 178 women not included in this review who 
received a 100 g glucose polymer screening test followed by a 100 g GTT using 
glucose polymer. 
Study dates: not reported. 
Funding sources: not reported; declarations of interest: not reported. 




Support for judgement 




'Randomised'; no further information was reported. 




Concealment of allocation was not reported. 
Incomplete outcome data (attrition 
bias) 
Low risk No women were lost to follow-up. 
Selective reporting (reporting bias) Low risk Specified outcomes have been reported. 
Other bias Low risk No significant group differences in baseline characteristics were noted. 
Blinding of participants and 
personnel (performance bias) 
Low risk Blinding of personnel and participants was not reported but was possible 
because the tests consisted of glucose drinks and could have appeared 
to be identical outcomes of plasma glucose value and of birthweight 
would not have been affected by knowledge of treatment groups. 
Blinding of outcome assessment 
(detection bias) 
Low risk Blinding of outcome assessors was not stated. Outcomes of plasma 
glucose value and birthweight would not have been affected by 
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Methods 'Randomly selected'; no further information was given. 
45 women (15%) were lost to follow-up. 
Participants 293 consecutive women at ≥ 28 weeks' gestation. 
Excluded: women with diabetes, women taking drugs that might influence glucose 
tolerance. 
Settings: Antenatal clinic, Lagos University Teaching Hospital, Nigeria. 
Interventions Experimental: 138 women, 75 g OGTT, WHO 1980 criteria. 
Control: 110 women, 100 g OGTT, NDDG 1979 criteria. 
In both groups women fasted for 8 hours before they were given the GTT. 
Outcomes Women: GDM, 1-, 2- and 3-hour blood glucose. 
Babies: macrosomia. 
Notes 2 women could not tolerate the glucose drink because of vomiting and contractions. 
For the 75 g GTT, GDM was diagnosed using WHO criteria. For the 100 g GTT, GDM 
was diagnosed using National Diabetes Data Group criteria. 
Attempts to contact study authors for clarification of outcomes were unsuccessful. 
Study dates: November 1997 to July 1999. 
Funding sources: not reported; declarations of interest: not reported. 




Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk 'Randomly selected'; no further information was given. 
Allocation concealment (selection 
bias) 
Unclear risk Allocation concealment was not reported. 
Incomplete outcome data (attrition 
bias) 
High risk 293 were recruited but only 248 completed; 45 were lost (15%). In Table 
2 study authors report data for only 25 of 138 women for the 3-hour 
glucose level in the 75 g group; no data for this outcome are missing for 
the 100 g group. 
Selective reporting (reporting bias) Low risk Specified outcomes of blood glucose values and macrosomia were 
reported. 
Other bias Low risk No significant group differences in baseline characteristics were reported. 
Blinding of participants and 
personnel (performance bias) 
Low risk Blinding of participants and personnel was not reported but was possible, 
as both tests were glucose drinks and could have appeared to be 
identical. Outcomes would not have been affected by knowledge of 
treatment groups. 
Blinding of outcome assessment 
(detection bias) 
Low risk Blinding of outcome assessors was not reported. Outcomes of blood 
glucose values and birthweight would not have been affected by 
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Methods Prospective, non-blind, parallel-group randomised controlled trial. Block randomisation 
used. 
Participants 736 pregnant women between 11 and 14 weeks of gestation. 
Settings: Antenatal outpatient clinic, Ankara, Turkey. 
Interventions Fasting plasma glucose obtained from all women at recruitment (8 to 14 weeks). 
Randomisation and intervention at 11 to 14 weeks. 
Experimental intervention 1: 377 women, 2-step method: 50 g GCT ± 100 g GTT. 
Experimental intervention 2: 349 women, 1-step method: 75 g GTT. 
All women not lost to follow-up, withdrawn or diagnosed with GDM received the 
allocated intervention again at 24 to 28 weeks' gestation. 
Outcomes GDM diagnosis. 
Notes Study dates: 31 December 2010 to 31 December 2011. 
Funding sources: not reported; declarations of interest: “The authors report no conflicts 
of interest”. 




Support for judgement 
Random sequence generation 
(selection bias) 
Low risk Block randomisation with blocks of 4 to ensure each group consisted of 
an equal number of participants. Blocks were chosen randomly using 
computer generated random numbers. 
Allocation concealment (selection 
bias) 
Unclear risk Unclear if allocation was concealed. Women in same block may have pre- 
empted which group they would be in. 
Incomplete outcome data (attrition 
bias) 
Low risk 7 and 4 women in the 2 and 1-step groups respectively who experienced 
fetal loss before 24 to 28 weeks were withdrawn. 132 and 107 women in 
the 2- and 1-step groups respectively were lost to follow-up (before 24 to 
28 weeks). However we only include the outcome rates reported prior to 
losses to follow-up. 
Selective reporting (reporting bias) Low risk Protocol not available, however the aim to evaluate the performance of 
screening tests for GDM is clearly stated. 
Other bias High risk Baseline characteristics reported only for those not lost to follow up or 
withdrawn (60% of recruited population). 
Blinding of participants and 
personnel (performance bias) 
Unclear risk Because the tests are clearly different the women and those administering 
the tests can not be blinded to the intervention allocation, however as the 
only relevant outcome reported (GDM diagnosis) is a biochemical 
assessment it is not possible for this to be influenced. 
Blinding of outcome assessment 
(detection bias) 
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Methods Consecutive numbers were obtained from a random number table. 
No losses to follow-up were reported, although 10 women did not complete the 
questionnaire on side effects. O'Sullivan 1964 criteria were used to diagnose GDM. 
Participants 76 Native Alaskan women at 24 to 28 weeks' gestation without a history of diabetes. 
Settings: Ketchikan Native Health Clinic and Mt. Edgecumbe Hospital, Alaska, USA. 
Interventions Experimental: 35 women; 50 g glucose polymer drink. 
Control: 41 women; 50 g glucose monomer drink. 
Outcomes Women: mean 1 hour venous plasma glucose, side effects. 
Babies: none reported. 
Notes Study dates: January 1988 to May 1990. 
Funding sources: grant from the Diabetes Research and Education Foundation, 
Bridgewater, NJ; declarations of interest: not reported. 




Support for judgement 
Random sequence generation 
(selection bias) 
Low risk Consecutive numbers from a random number table. 
Allocation concealment (selection 
bias) 
Unclear risk Allocation concealment was not reported, although study was described 
as "double blind". 
Incomplete outcome data (attrition 
bias) 
Low risk No losses to follow-up were reported, although 10 women did not 
complete the questionnaire on side effects. 
Selective reporting (reporting bias) Low risk Specified outcomes of side effects and plasma glucose values were 
reported. 
Other bias Unclear risk No table of participants' baseline characteristics was provided to permit 
judgement of the effectiveness of randomisation. 
Blinding of participants and 
personnel (performance bias) 
Unclear risk Study was described as double blind, which is possible as test drinks 
may have appeared identical. Outcomes of side effects could have been 
affected by knowledge of treatment groups, but the plasma glucose value 
would not have been affected. 
Blinding of outcome assessment 
(detection bias) 
Low risk Study was described as double blind. Side effects were self-reported on a 
questionnaire and thus were not subject to assessor bias. Plasma 
glucose values would not have been affected by lack of blinding on the 
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Methods 'Prospectively enrolled and randomly assigned'; no further information was given. 
3-arm comparison trial. 
Participants 124 women having GDM screening at 24 to 28 weeks' gestation or women at high risk 
at initial antenatal visit; partial initial outcome data reported following screening of 122 
women O'Sullivan 1964 criteria were used to diagnose GDM. 
Settings: Medical Education Clinics, Saint Luke's Hospital, Kansas City, Missouri, 
USA. 
Interventions Experimental group 1: 40 women, 50 g glucose polymer. 
Experimental group 2: 39 women, candy bars as a screening test. 
Control: 43 women, 50 g standard d-glucose. 
In all groups the intervention was non-fasting, regardless of when the last meal was 
eaten. Serum glucose at 1 hour, then 100 g oral GTT within 1 week, 16 were unable to 
complete the GTT; 5 because of vomiting and 11 for logistical or laboratory reasons. 
Outcomes Women: serum glucose at 1 hour ≥ 7.5 mmol/L, rating for taste and adverse 
symptoms (including pain, bloating, dizziness and nausea). 
Babies: none reported. 
Notes 5 women required nursing assistance to complete the GTT. Control group data were 
divided (to prevent double counting) and were compared with data from the 2 
experimental groups. 
Study dates: not reported. 
Funding sources: research grant from St Luke’s Foundation; declarations of interest: 
not reported. 




Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk 'Randomly assigned'; no further information was given. 
Allocation concealment (selection 
bias) 
Unclear risk Concealment of allocation was not reported. 
Incomplete outcome data (attrition 
bias) 
High risk 16/124 (13%) did not have a GTT (5 because of vomiting, 11 for 
'logistical' reasons or because of incomplete laboratory data). 14/108 
(13%) women did not complete the post-test questionnaire. 
Selective reporting (reporting bias) Low risk Specified outcomes of serum glucose at 1 hour and questionnaire for 
taste and symptoms were reported. 
Other bias High risk Differences in group characteristics were significant for age and parity 
(younger and lower parity women received candy bars). 
Blinding of participants and 
personnel (performance bias) 
High risk Blinding was not reported, but treatments were visibly different (candy 
bar vs solution). Reporting of side effects could have been affected by 
knowledge of treatment groups, but serum glucose value would not have 
been affected. 
Blinding of outcome assessment 
(detection bias) 
Unclear risk Blinding was not reported. Symptoms were self-reported on a 
questionnaire and were not subject to assessor bias. Plasma glucose 
values would not have been affected by lack of blinding on the part of 
assessors. 
Footnotes 
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ADA: American Diabetes Association 
d-glucose: glucose monomer 
GDM: gestational diabetes mellitus 
GTT: glucose tolerance test 
OGTT: oral glucose tolerance test 
SD: standard deviation 
vs: versus 
WHO: World Health Organization 
Characteristics of excluded studies 
Austria 1994 
Reason for exclusion Not a randomised trial; cross-over design and comparison of different ways of 
measuring blood glucose. 
Participants: 500 women having an OGTT, usually at 24 to 28 weeks' gestation, but 
some earlier and a few later or postpartum. 
Austria 1998 
Reason for exclusion Cross-over study of response to different glucose loads in those with a diagnosis of 
GDM and those without. 
Participants: 60 women, 30 with GDM and willing to undergo a second GTT and 30 
healthy pregnant women. 
Interventions: 75 g OGTT vs 100 g OGTT. 
Canada 1999 
Reason for exclusion Wrong intervention: routine screening of all women vs selective screening for clinical 
indications of GDM. 
Participants: 2401 low-risk women randomly assigned to screening, or screening only 
if a clinical indication arose during pregnancy. 
Interventions: routine screening with 50 g OGTT vs screening with 100 g OGTT only if 
indicated. 
Outcome: macrosomia rate. 
Canada 2005 
Reason for exclusion Outcomes reported as percentage rates. 
Participants: 5489 women. 
Interventions: 50 g OGTT and 100 g OGTT vs 50 g OGTT and 75 g OGTT vs 75 g 
OGTT. 
Canada 2010 subset of Canada 2005. 
Outcomes: economic evaluation of 1-step and 2-step screening and diagnostic 
approaches, no evaluation of maternal and infant outcomes. 
Participants: 1594 women. 
Intervention: as above. 
China 1995 
Reason for exclusion Not a randomised trial; women 'randomly selected' for a 50 g OGTT. 
Participants: 220 women in the third trimester. 
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Reason for exclusion Not a randomised trial. 
Participants: 622 women at 28 to 32 weeks. 
Interventions: 50 g OGTT if results > 7.78 mmol/L, then 75 g OGTT. 
Germany 2004 
Reason for exclusion Cross-over trial; no clinical outcomes reported. 
Participants: 34 women at around 30 weeks' gestation, unselected. 
Interventions: low- vs high-carbohydrate diet before OGTT. 
Greece 2004 
Reason for exclusion Not a randomised trial: 2 groups matched for key characteristics. No clinical outcomes 
reported. 
Participants: 47 women undergoing 100 g OGTT at 24 to 28 weeks. 
Interventions: fingertip vs forearm blood sample. 
Hong Kong 1993 
Reason for exclusion Cross-over trial; participants randomly assigned to the order in which they were given 
50 g and 75 g OGTT. 
Participants: 50 women at 28 to 32 weeks' gestation. 
Interventions: 50 g OGTT and 75 g OGTT. 
Iran 2007 
Reason for exclusion Cross-over trial. 
Participants: 141 women at 24 to 28 weeks' gestation if low risk. 
Interventions: breakfast containing 50 g simple glucose vs 50 g glucose challenge. 
Iran 2008 
Reason for exclusion Cross-over trial. 
Participants: 138 women. 
Intervention: 50 g OGTT vs breakfast (includes 50 g sugar or jam). 
Ireland 2000 
Reason for exclusion Wrong intervention. Universal screening vs selective screening. 
Participants: 3742 women at booking visit. 
Interventions: universal vs selective screening for GDM. 
Ireland 2014a 
Reason for exclusion Trial comparing identification of gestational diabetes using OGTT in primary and 
secondary care settings. 
New Zealand 1984a 
Reason for exclusion Cross-over trial; 2 studies reported in the same paper. 
Participants: 26 women; consecutive referrals for carbohydrate tolerance testing 
because of risk factors for GDM. 
Interventions: 50 g OGTT vs 50 g glucose polymer tolerance test. 
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New Zealand 1984b 
Reason for exclusion Cross-over trial; 2 studies reported in the same paper. 
Participants: 20 women; consecutive referrals for carbohydrate tolerance testing 
because of features suggestive of GDM. 
Interventions: 50 g glucose polymer vs 50 g glucose. 
Singapore 1992 
Reason for exclusion Cross-over trial. 
Participants: 56 women in the third trimester. 
Interventions: 50 g OGTT vs 75 g OGTT. 
Thailand 1995 
Reason for exclusion Not a randomised trial. 
Participants: 709 women. 
Interventions: 50 g OGTT and 75 g OGTT within a week, then 100 g if 50 g OGTT 
blood sugar ≥ 7.8 within a week of the 75 g OGTT. 
Thailand 2003 
Reason for exclusion Cross-over trial. 
Participants: 42 women with a positive 50 g glucose challenge test at 14 to 36 weeks. 
Interventions: 75 g OGTT vs 100 g OGTT. 
Thailand 2008 
Reason for exclusion Participants known to have normal glucose tolerance. 
Participants: 41 women with normal 100 g OGTT and 25 women with normal 75 g 
OGTT. 
Interventions: 75 g vs 100 g OGTT - postload blood glucose levels. 
Tunisia 2001 
Reason for exclusion Cross-over trial. 
Participants: 100 women at 24 to 28 weeks. 
Interventions: meal and 50 g oral glucose as screening for GDM. 
USA 1989 
Reason for exclusion Quasi-randomised study using alternate allocations. Also, cross-over design and 42% 
lost to follow-up. 
Participants: 114 women ≤ 24 weeks' gestation. 
Interventions: 50 g vs 100 g OGTT. 
USA 1991 
Reason for exclusion Quasi-randomised study using alternate allocations and a cross-over design. 
Participants: 37 women at 10 to 38 weeks' gestation. 
Interventions: 50 g OGTT if result ≥ 135 mg/dL, then 3-day diet of > 150 g/d of CHO, 
then > 1 week of normal diet before 50 g OGTT or > 1 week of normal diet plus 3-day 
diet of > 150 g/d of CHO before 50 g OGTT. 
USA 1993a 
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Reason for exclusion Cross-over trial; published as abstract only. 
Participants: 45 women with an abnormal glucose challenge screening test. 
Interventions: '3-hour standard' OGTT vs intravenous GTT. 
USA 1993b 
Reason for exclusion Cross-over trial. 
Participants: 26 low-risk women at 28 to 32 weeks' gestation. 
Interventions: non-fasting OGTT vs fasting OGTT. 
USA 1993c 
Reason for exclusion Not a randomised trial. Case series in which all women were given both tests. 
Participants: 32 women at 26 to 36 weeks' gestation. 
Interventions: 75 g OGTT vs 100 g OGTT. 
USA 1995 
Reason for exclusion Not a randomised trial, cross-over design. 
Participants: 32 women at 26 to 36 weeks' gestation. 
Interventions: 100 g then 75 g OGTT. 
USA 1995a 
Reason for exclusion Outcomes data reported by whether or not the women had GDM, not by allocated 
group. 
Participants: 80 women with a positive 50 g glucose challenge test. 
Interventions: 75 g OGTT vs 50 g OGTT. 
USA 1999 
Reason for exclusion Cross-over trial. 
Participants: 160 women at 24 to 28 weeks' gestation. 
Interventions: 30 jelly beans vs 50 g glucose drink. 
USA 2001 
Reason for exclusion Participants were women with a diagnosis of gestational diabetes. 
USA 2015 
Reason for exclusion Brieft abstract only. 
Participants: women with increased BMI (> 25) at 16 weeks' gestation. 
Intervention: early testing of glucose intolerance and provision of an intervention to 
reduce the risk of GDM (prevention intervention). 
Footnotes 
BMI: body mass index 
CHO: carbohydrate 
GDM: gestational diabetes mellitus 
GTT: glucose tolerance test 
OGTT: oral glucose tolerance test 
vs: versus 
Characteristics of studies awaiting classification 
28 / 48 
 China 2013 
Different strategies for diagnosing gestational diabetes to improve maternal and infant health 
 
Methods Randomised parallel control trial (no details given). 
Participants Women at high risk of diabetes - increased BMI, relative with diabetes, polycystic 
ovarian syndrome, history of GDM (not clear if history of GDM was in current or 
previous pregnancy). 
Interventions Early screening then diet control vs advanced screening them insulin (not clear what 
advanced screening is). 
Outcomes Glycated haemoglobin (HbA1C) 
Oral glucose tolerance 
C-peptide 
Low density lipoprotein 
Triglycerides 
Insulin 
Homeostatic model assessment insulin resistance 
Mean glucose value 
Mean blood glucose 
Body mass index 
Post prandial glucose estimation 
Systolic blood pressure 
Diastolic blood pressure 
Apgar score at 5 minutes 
Notes Awaiting assessment pending further publications or information from the authors. 
Footnotes 
GDM: gestational diabetes mellitus 
vs: versus 
Characteristics of ongoing studies 
Ireland 2014b 
Study name Not known. Interim analysis of ongoing trial. 
Methods Described as 'randomly allocated'. No further details given (conference abstract only). 
Participants Pregnant women offered universal testing for GDM. 
Interventions Non-fasting 50 g glucose challenge test vs fasting 75 g OGTT. 
Outcomes Number diagnosed with GDM 
Change in HbA1c (mmol/mol) 
Rise in HbA1c > 10% 
Starting date 2014. 
Contact information T Ahern, Diabetes Centre, Midlands Regional Hospital, Mullingar, Co Westmeath. 
Notes  
USA 2013 
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Study name USA 2013. 
Methods Randomised trial. 
Participants 1160 obese (BMI ≥ 30) pregnant women. 
Interventions Routine (OGTT at 24 to 28 weeks) vs early (OGTT at 14 to 18 weeks with repeat 
testing at 24 to 28 weeks for negative women) testing to identify gestational diabetes. 
Outcomes Composite perinatal outcome (macrosomia > 4 kg, gestational hypertension, pre- 
eclampsia, shoulder dystocia, hyperbilirubinaemia, neonatal hypoglycaemia < 40 
mg/dL), macrosomia > 4 kg, primary caesarean, pregnancy-induced hypertension 
(gestational hypertension, pre-eclampsia), shoulder dystocia, hyperbilirubinaemia, 
neonatal hypoglycaemia < 40 mg/dL, preterm birth < 37 weeks' gestation. 
Starting date June 2013. 
Contact information lmharper@uabmc.edu University of Alabama at Birmingham, USA. 
Notes  
USA 2014 
Study name Not known. 
Methods Randomised double blind trial. 
Participants All pregnant women who did not have a diagnosis of diabetes. Following a 1 hour 50 g 
glucose challenge test at between 24 to 28 weeks' gestation. Women with results < 20 
mg/dL randomised to 1 of 2 groups. 
Interventions Fasting 2 hour 75 g OGTT and the IADPSG criteria vs fasting 3 hour 100 g OGTT and 
diagnosed with Carpenter Coustan criteria. 
Outcomes Large for gestational age infant 
Birthweight greater than the 90th percentile for gestational age 
Caesarean delivery 
Maternal composite morbidity - maternal pre-eclampsia, 3rd or 4th degree vaginal 
lacerations, postpartum haemorrhage 
Neonatal composite morbidity 
Starting date 2014. 
Contact information Esa Davis: davisem@upmc.edu 
Notes Estimated primary completion date: December 2018. 
Footnotes 
BMI: body mass index 
GDM: gestational diabetes mellitus 
IADPSG: International Association of Diabetes and Pregnancy Study Group 
OGTT: oral glucose tolerance test 
vs: versus 
Summary of findings tables 
1 75 g OGTT versus 100 g OGTT for diagnosing GDM to improve maternal and infant health 
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75 g oral glucose tolerance test (OGTT) versus 100 g OGTT for diagnosing gestational diabetes mellitus (GDM) to improve 
maternal and infant health 
Patient or population: pregnant women at low or high risk of gestational diabetes 
Settings: 1 study, Nigeria 
Intervention: 75 g OGTT 
Comparison: 100 g OGTT 
Outcomes Illustrative comparative 
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comment 






None of the included studies 
reported this outcome. 
*The basis for the assumed risk (e.g. median control group risk across studies) is the risk. The corresponding risk (and its 
95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention 
(and its 95% CI). 
CI: Confidence interval; RR: Risk ratio. 
GRADE Working Group grades of evidence. 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may 
change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is 
likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
Footnotes 
aOne study with design limitations (-1). 
bWide confidence intervals crossing the line of no effect, few events and small sample size. 
Additional tables 
1 International Association of Diabetes and Pregnancy Study Groups (IADPSG) 
Time Plasma 
Fasting glucose (≥) 5.1 mmol/L 
1-hour glucose (≥) 10.0 mmol/L 
2-hour glucose (≥) 8.5 mmol/L 
Footnotes 
IADPSG cutoff levels for diagnosis of gestational diabetes for plasma glucose; gestational diabetes is diagnosed if 
any one value equals or exceeds any other value (Metzger 2010). World Health Organization (WHO) published revised 
guidance in 2013 recommended IADPSG cutoff levels for the diagnosis of gestational diabetes (WHO 2013). 
2 World Health Organization criteria for 75 g OGTT 
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Time Whole blood venous Whole blood capillary Plasma venous Plasma capillary 
Fasting glucose (≥) 6.1 mmol/L 6.1 mmol/L 7.0 mmol/L 7.0 mmol/L 
2-hour glucose 6.7 mmol/L 7.8 mmol/L 7.8 mmol/L 8.9 mmol/L 
Footnotes 
Cutoff levels for diagnosis of gestational diabetes for whole blood and plasma glucose. Diabetes is diagnosed if fasting 
plasma glucose level is > 7.0 mmol/L, or if 2-hour level is > 11.1 mmol/L (WHO 1999). 
3 Alternative criteria for the 100 g oral GTT 
Time O'Sullivan 1964 a NDDG 1997 b Carpenter 1982 c 
Fasting glucose (≥) 5.0 mmol/L 5.8 mmol/L 5.3 mmol/L 
1-hour glucose (≥) 9.1 mmol/L 10.0 mmol/L 10.0 mmol/L 
2-hour glucose (≥) 8.0 mmol/L 9.1 mmol/L 8.6 mmol/L 
3-hour glucose (≥) 6.9 mmol/L 8.0 mmol/L 7.8 mmol/L 
Footnotes 
Gestational diabetes is diagnosed when two or more measurements in a single column exceed stated cutoff levels. 
a O'Sullivan 1964: cutoff levels for diagnosis of gestational diabetes for whole blood. 
b NDDG 1997: cutoff for diagnosis of gestational diabetes for plasma glucose. 
c Carpenter 1982: cutoff for diagnosis of gestational diabetes for plasma glucose. 
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Classification pending references 
Data and analyses 
1 75 g OGTT versus 100 g OGTT 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
1.1 Diagnosis of gestational 
diabetes 
1 248 Risk Ratio(M-H, Fixed, 95% CI) 2.55 [0.96, 6.75] 
1.2 Plasma glucose (mmol/L) 1  Mean Difference(IV, Fixed, 90% CI) Subtotals only 
1.2.1 At 1 hour 1 248 Mean Difference(IV, Fixed, 90% CI) -0.11 [-0.44, 0.22] 
1.2.2 At 2 hours 1 248 Mean Difference(IV, Fixed, 90% CI) -0.31 [-0.64, 0.02] 
1.2.3 At 3 hours 1 248 Mean Difference(IV, Fixed, 90% CI) -1.08 [-1.47, -0.69] 
2 50 g glucose polymer drink versus 50 g glucose monomer drink 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
2.1 Maternal side effects 2  Risk Ratio(M-H, Random, 95% CI) Subtotals only 
2.1.1 Nausea 1 66 Risk Ratio(M-H, Random, 95% CI) 0.29 [0.11, 0.78] 
2.1.2 Headache 1 66 Risk Ratio(M-H, Random, 95% CI) 0.20 [0.02, 1.62] 
2.1.3 Bloatedness 2 131 Risk Ratio(M-H, Random, 95% CI) 0.33 [0.04, 2.60] 
2.1.4 Dizziness 1 66 Risk Ratio(M-H, Random, 95% CI) 0.40 [0.08, 1.92] 
2.1.5 Tiredness 1 66 Risk Ratio(M-H, Random, 95% CI) 1.33 [0.32, 5.50] 
2.1.6 Vomiting 1 66 Risk Ratio(M-H, Random, 95% CI) Not estimable 
2.1.7 Pain 2 129 Risk Ratio(M-H, Random, 95% CI) 0.14 [0.02, 1.15] 
2.1.8 Total number of side effects 1 63 Risk Ratio(M-H, Random, 95% CI) 0.21 [0.07, 0.59] 
2.1.9 Taste 1 63 Risk Ratio(M-H, Random, 95% CI) 0.99 [0.76, 1.29] 
2.2 Plasma glucose (mmol/L) 3  
Mean Difference(IV, Random, 95% 
CI) 
Subtotals only 
2.2.1 At 1, 2 and 3 hours 3 239 
Mean Difference(IV, Random, 95% 
CI) 
-0.20 [-0.71, 0.32] 
2.2.2 At 2 hours 1 100 
Mean Difference(IV, Random, 95% 
CI) 
-0.40 [-0.85, 0.05] 
2.2.3 At 3 hours 1 100 
Mean Difference(IV, Random, 95% 
CI) 
0.00 [-0.45, 0.45] 
2.3 Gestational age at birth (weeks) 1 100 Mean Difference(IV, Fixed, 95% CI) -0.80 [-1.69, 0.09] 
3 Candy bar versus 50 g glucose monomer drink 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
3.1 Maternal side effects 1  Risk Ratio(M-H, Fixed, 95% CI) Subtotals only 
3.1.1 Pain 1 58 Risk Ratio(M-H, Fixed, 95% CI) 0.17 [0.01, 3.91] 
3.1.2 Bloatedness 1 60 Risk Ratio(M-H, Fixed, 95% CI) 1.08 [0.21, 5.40] 
3.1.3 Total side effects 1 58 Risk Ratio(M-H, Fixed, 95% CI) 1.03 [0.58, 1.82] 
3.1.4 Taste 1 59 Risk Ratio(M-H, Fixed, 95% CI) 0.60 [0.42, 0.86] 
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3.2 1-hour serum glucose level 
(mmol/L) 
1 59 Mean Difference(IV, Fixed, 95% CI) -1.00 [-1.13, -0.87] 
4 50 g glucose in food versus 50 g glucose drink 
 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
4.1 Maternal side effects 1 30 Risk Ratio(M-H, Fixed, 95% CI) 0.08 [0.01, 0.56] 
4.2 Need for repeat testing by same 
or alternative method 
1 30 Risk Ratio(M-H, Fixed, 95% CI) 0.14 [0.01, 2.55] 
5 75 g OGTT (WHO criteria) versus 75 g OGTT (ADA criteria) 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
5.1 Caesarean section 1 116 Risk Ratio(M-H, Fixed, 95% CI) 1.07 [0.85, 1.35] 
5.2 Instrumental delivery 1 116 Risk Ratio(M-H, Fixed, 95% CI) 0.21 [0.01, 3.94] 
5.3 Diagnosis of gestational 
diabetes 
1 116 Risk Ratio(M-H, Fixed, 95% CI) 1.47 [0.66, 3.25] 
5.4 Macrosomia 1 116 Risk Ratio(M-H, Fixed, 95% CI) 0.73 [0.19, 2.79] 
5.5 Stillbirth 1 116 Risk Ratio(M-H, Fixed, 95% CI) 0.49 [0.02, 11.68] 
6 Two-step (50 g OGCT and 100 g OGTT) versus one-step (75 g OGTT) approach 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
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Risk of bias summary: review authors' judgements about each risk of bias item for each included study. 
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2..1 Maternal side effects. 
 
51lg glucose polymer 51lg ,glucose monomer Risk Ratio  Risk Ratio 
Study or Subgroup Events Tota.I  Ev,e nts Tota.II  Weight   M,H, Random, 95% 01 M-H, Random, 95% Cl 
2.1.1 tiausea 
USA 1992 4 33 14 33    100.0% 0.29 [O 11, 0 78] 
Subtotall ,f95%Cl) 33 33  10D.0% 0.29> [ll.11 , (H8l 
TotaI events 4 14 
Heterogeneity: Not applicable 
Test for overall effect: Z = 2.45 (P = 0.01) 
 
2.1..2 Headache 
USA 1992 33 5 33  100.0% 0.20 [0.02, 1 62] 
Subtotal 195% C l) 33 33   10D.0% 0..21), [ll.0.2, 1.62l 
TotaI events 5 
Heterogeneity: Not applicable 
Testfor overall effect: Z = 1.51 (P = 0.1 3) 
 
2.1.3 Bl.oa.tedness. 
USA 1992 4 33 6 33     68.4% 0.67 [0.21, 2.15] 
USA 1994 0 43 3 22     31.6% 0.07 [O 00, 1 38] 
Subtotal·195% Cl) 76 55   10D.0% 0.33  [ll ..o4, 2.60] 
TotaI events 4 9 
Heterogeneity:Tau'= 1.25; Chi'= 1.97, df= 1 (P = 0.16); I'= 49% 
Testfor overall effect: Z = 1.05 (P = 0.29) 
 
2.1.4 Dininess 
USA 1992 2 33 5 33   100.0% 0.40 [0.08, 1 92] 
Subtotall ,f95%Cl) 33 33   10D.0% 0.40  [ll.0 8, 1.92l 
TotaI events 2 5 
Heterogeneity: Not applicable 
Test for overall effect: Z =  1.15  (P =  O 25 ) 
 
2.1 . 5 Tir,e dnes.s 
 
USA 1992 4 33 3 33 100.0% 1.33 [0.32, 5.50] 




33 10D.0% 1.33 [ll ..32, 5.50] 
TotaI events 4 
 
3 
   Heterogeneity: Not applicable 
      Test for overall effect Z = 0.40 (P = 0.69) 
2.1.6 Vomiting      





33 Not estimab le 
TotaI events 0 
 
0 
  Heterogeneity: Not applicable 
     Testfor overall effect: Not  applicable 
2.1.7 Pain       
USA 1992 0 33 2 33 49.9% 0.20 [O 01,  4 01] 





53 10D.0% 0.14 [ll ..02, 1.15j 
TotaI events 0 
 
4 
   
Heterogeneity: Tau'= 0.00; Chi'= 0.12, df= 1 (P = 0.73); I'= 0% 
Test for overall effect: Z = 1.83 (P = 0.07) 
 
2.1.8 T,ota.l number of side effects 





20 10D.0% 0..21 [ll ..07 , D.59] 
Tot aI events 4 
 
9 
   Heterogeneity: Not applicable 
      Test for overall effect: Z =  2.94  (P = 0.003) 
2.1.9 Taste       





20 10D.0% 0.99•[ll.716  , 1.29] 
TotaI events 34 
 
16 
   Heterogenei ty: Not  applicable 
      Test for overall effect: Z =  0.09 (P = 0.93) 
 
0.005 0.1 10 
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